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Background:  Rotavirus specific maternal antibodies acquired passively via placental 
and/or breast milk may contribute to the reduced oral rotavirus vaccine efficacy 
observed in children in developing countries. This study aimed to investigate the effect 
of rotavirus specific maternal antibodies on the serum IgA response or stool excretion 
of vaccine virus after any dose of an oral neonatal rotavirus vaccine, RV3-BB, in 
parallel to a Phase IIa clinical trial conducted at Dunedin Hospital, New Zealand. 
Methods:  Rotavirus specific IgG and serum neutralizing antibody (SNA) levels in cord 
blood and IgA levels in colostrum and breast milk samples collected ~4 weeks, ~20 
weeks and ~28 weeks after birth were measured. Infants were randomised to receive 
the first dose of vaccine at 0–5 days after birth (neonatal schedule) or at 8 weeks 
(infant schedule). Breast feeding was with-held for 30 minutes before and after 
vaccine administration. Data for IgA response and stool vaccine virus excretion after 
RV3-BB rotavirus vaccine was obtained from the Phase IIa clinical trial.  The 
relationship between rotavirus specific IgA in colostrum or breast milk at the time of 
first active dose of RV3-BB vaccine and rotavirus specific IgG and SNA levels in cord 
blood, and level of IgA response and stool vaccine virus excretion after three doses of 
vaccine was assessed using linear and logistic regression.  The relationship between 
rotavirus specific IgA in colostrum and rotavirus specific IgG and SNA levels in cord 
blood, and level of IgA response and stool vaccine virus excretion after a single 
neonatal dose of vaccine in the neonatal schedule group was also assessed. 
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Results:  Twenty one infants in the neonatal schedule group and 19 infants in the 
infant schedule group received 3 doses of RV3-BB rotavirus vaccine and were included 
in the analysis. Rotavirus specific IgA in colostrum and breast milk at 4 weeks was 
identified in 14/21 (67%) and 14/17 (82%) of infants in the neonatal and infant 
schedule groups respectively.  IgA responses after 3 doses were identified in 76% and 
74% of infants in the neonatal and infant groups, stool excretion of vaccine virus in 71% 
and 79% of infants.  There was no evidence of an association between IgA in 
colostrum or breast milk IgA at 4 weeks and IgA response or stool excretion after 
three doses of RV3-BB, or after one dose (neonatal schedule). There was little 
evidence of an association between cord IgG or SNA level and level of IgA response 
and stool excretion after one neonatal dose or after 3 doses of RV3-BB. 
Conclusions:  The level of IgA in colostrum or breast milk and placental IgG and SNA 
did not affect the serum IgA response or stool excretion following three doses of RV3-
BB Rotavirus Vaccine administered using a neonatal or infant schedule in New Zealand 
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Rotaviruses are members of the Rotavirus genus, of the Reoviridae family.  Rotavirus 
particles are 70-nm in size, and of icosahedral shape (fig.1).  Each particle has 3 
concentric protein layers (an outer and inner capsid and a core) that surrounds the 
viral genome (fig.2).  The rotavirus genome is made up of 11 segments of double-
stranded RNA, which encode 6 structural proteins (viral proteins [VPs]) that make up 
the virus particles and 6 non-structural proteins (NSPs) (1).   
 
Figure 1 TEM of intact rotavirus particles from CDC Public Health Image Library 
 




The two outer capsid or surface proteins, VP7 and VP4, segregate in various 
conformations, and form the basis of a binary classification system for rotavirus 
serotypes.  Serotypes determined by the VP7 protein are termed G types, serotypes or 
[genotypes] (genotypes designated in brackets) determined by the VP4 protein are 
termed P types.  P serotypes and genotypes are not always equivalent.  To date, at 
least 15 G, 14 P serotypes and 25 P genotypes have been identified (2).  Despite more 
than 60 G-P combinations ever found at least once in rotaviruses isolated from human 
beings, only 5 strains (G1, G3, G4 or G9P1A[8], and G2P1A[4]) account for 80% to 90% 
of the childhood rotavirus disease burden globally (3, 4).  VP7 and VP4 elicit serotype 
specific neutralizing antibody responses, either antibody can mediate protection (2).  
VP7 and VP4 also elicit cross-reactive neutralizing antibodies (5-8).  However the 
nature of human cross reactive antibodies is poorly understood.  Two other rotavirus 
proteins of biological structural significance are VP6, an inner capsid protein that 
determines the major subgroup antigen (fig.2), and NSP4, a non-structural protein 




1.2 Rotavirus Pathogenesis 
The mechanism of rotavirus pathogenesis is not completely understood and varies 
depending on the animal model studied.  The following is a potential mechanism of 
pathogenesis.  Rotavirus infects mature non-dividing enterocytes near the tip of the 
villus in the mucosal surface of the small intestine.  Infection progresses from the 
proximal to the distal small intestine (3).  Following infection, rotavirus replicates in 
the cytoplasm of these cells, and releases NSP4 (enterotoxin).  The viral replication 
and the NSP4 destroy absorptive enterocytes, disrupt tight junctions allowing 
paracellular leakages of electrolytes followed passively by water, and also induce 
excess chloride secretions (and consequently water) via a calcium-dependent 
signalling pathway (1).   
Following a short incubation period of 1-3 days, the disease usually begins with 
sudden onset of watery diarrhoea, fever, and vomiting, either alone or in 
combination.  The spectrum of illness ranges from subclinical illness or mild, self-
limiting watery diarrhoea to severe dehydrating diarrhoea with vomiting, fever, 
electrolyte imbalance and metabolic acidosis.  If left untreated, this can lead to shock 
and death.  Compared with other causes of gastroenteritis, rotaviruses tend to cause 
more severe symptoms (9).  Treatment is by nonspecific supportive measures, such as 
oral or intravenous rehydration.  Gastrointestinal symptoms usually resolve within 3 to 
7 days (10).   
In the past, rotavirus infection was generally thought to be localised to the epithelial 
cells lining the small intestine especially in immune-competent persons.  However, 
studies have revealed that rotavirus spread outside the intestine is common, leading 
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to antigenaemia and viraemia (11, 12).  There have also been reports of rotavirus 
infection affecting the central nervous system (13-15), liver (16) and other sites (17). 
The exact mode of transmission of rotavirus is not clear.  Spread by faecal-oral route is 
believed to be the primary route, mostly through direct person-to person contact (18), 
but also by fomites (environmental surfaces contaminated by stools) (19, 20).  
Transmission through exposure to aerosolised respiratory droplets has also been 




1.3 Epidemiology of Rotavirus Gastroenteritis 
Worldwide, diarrhoea is the second most common cause of deaths in children under 
five, after pneumonia (23). Rotaviruses are the most common cause of severe 
diarrhoea in infants and young children, accounting for nearly one third of diarrhoeal 
deaths under five (24).  In 2011, the global mortality rate in children younger than 5 
years old attributable to rotavirus infection was estimated at 192 700 per annum (24).  
About 95% of rotavirus-related deaths occur in low-income countries of Asia and sub-
Saharan Africa (18).  India alone accounted for 22% of these deaths (18). 
In industrialised countries, while deaths from rotavirus are rare (18, 25), prior to 
introduction of rotavirus vaccines, rotaviruses were the most common cause of severe 
childhood diarrhoea, accounting for approximately 40% of acute gastroenteritis 
hospitalisations in children <5 years old (26-29).  In these countries, for every child 
admitted to hospital with rotavirus gastroenteritis, another 5-10 were managed in the 
primary health care (28).  Apart from differences in mortality rates, the incidence rate 
of rotavirus disease were comparable in both developing and developed countries 
(28).  Improvements in water, sanitation, and hygiene, have not decreased the overall 
incidence of rotavirus infections.   
Prior to the introduction of rotavirus vaccines, it  was estimated that rotavirus caused 
more than 114 million diarrhoea episodes per year globally, with approximately 24 
million clinic visits and 2.4 million hospitalisations in children aged under 5 (1, 28).  
The annual health and societal costs of rotavirus disease in the European Union was 
estimated at £550 million (30).  In the US, prior to introduction of rotavirus 
vaccination, an estimated 55 000 to 70 000 children under 5 years of age were 
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hospitalised per year for rotavirus infection.  The direct and indirect costs were 
approximately $890 million to $1 billion annually (31, 32).   
In New Zealand, prior to the inclusion of rotavirus vaccine in the National 
Immunisation Schedule in 2014, rotavirus accounted for approximately 43% of 
gastroenteritis admissions in children under 3 years of age (33).   The estimated 
annual rotavirus hospitalisation incidence was 476 per 100 000 children younger than 
5 years of age (34).  It was estimated that 1 in 43 New Zealand children were 
hospitalised with rotavirus gastroenteritis by 5 years of age, and 1 in 5 would have 
seen a medical practitioner for rotavirus gastroenteritis (34).  The annual societal cost 
of rotavirus disease in New Zealand was estimated at $7.07 million in 2009 (34).   
Almost all children will have had one or more episodes of rotavirus infection by 5 
years of age (28).  Most rotavirus diarrhoea occurs during the first 3 years.  Severe 
rotavirus diarrhoea is most likely in children 3 to 24 months of age who are 
experiencing their first infection (3, 35, 36).  Children in low-income settings seem to 
be infected earlier in life (37-39).  It is believed that the very young infants in the first 
few months of life may be partially protected by passively acquired maternal 
antibodies via placenta or breast milk.  However, symptomatic rotavirus 
gastroenteritis necessitating hospital visits is not uncommon in very young infants 
under 3 months of age (40-42).  This may occur when maternal antibodies are 
overwhelmed by an extremely high viral load, for example in areas endemic of 
rotavirus disease.  In these circumstances maternal antibodies, although inadequate in 
titre to offer protection against infection, might potentially interfere with infant’s 
antibody response to live vaccines (43, 44) (also refer Chapter 1.7). 
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In countries with a temperate climate, rotavirus infections display seasonality with 
peak infections occurring in the cooler months from late autumn through to early 
spring.  In contrast, seasonality is less marked closer to the equator where disease is 






Clinical protection to rotavirus following previous natural symptomatic or 
asymptomatic rotavirus infections has been demonstrated in various studies. One of 
the earliest studies demonstrating this result was a prospective longitudinal study 
conducted in the late 1970s and early 1980s in Australia (48).  This study published in 
1983 demonstrated that early infection of neonates with rotavirus in the first month 
of life, even though not protective against reinfection, was protective against severe 
disease on reinfection when followed up to three years.  Those not infected in the first 
month of life were not protected from severe disease with the first rotavirus infection.   
A cohort study in Mexico demonstrated natural rotavirus infection conferring 
protection against subsequent infection and disease, with greatest protection against 
moderate-to-severe disease.  After two natural infections, this cohort of infants 
appeared to acquire complete protection against moderate-to-severe disease when 
followed up to two years (49).  In India, a recent study revealed that protection against 
moderate or severe disease was 79% after three natural infections (38).   
In mammals, there are five immunoglobulin isotypes: IgM, IgG, IgA, IgD and IgE.    IgG 
is the most abundant antibody in normal human serum, and is present in all internal 
body fluids.  IgA is the major protective immunoglobulin of external secretions of 
gastrointestinal, respiratory and urogenital tracts, but is also present in the circulation. 
The presence of IgA in external secretions (secretory IgA (sIgA)) enables it to neutralise 
pathogens to prevent infection at mucosal sites of the body (1). 
The exact mechanism of immunity after natural rotavirus infection is not fully 
understood.  Protection from rotavirus has been associated with production of 
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rotavirus-specific secretory IgA at the intestinal mucosal surface (50), probably by 
rotavirus-specific memory B cells in the intestinal lamina propria.  Increased serum 
titres of rotavirus-specific IgA, IgM and IgG are also observed following natural 
rotavirus infections, probably as a result of systemic immune response from 
antigenaemia and viraemia (2).  Presence of serum antibodies does not necessarily 
confer immunity.  Rotavirus-specific serum IgG level has not correlated with protective 
efficacy.  Rotavirus-specific serum IgA level does not always correlate with rotavirus-
specific secretory IgA antibody level at the intestinal surface, but is probably the best 
correlate (2, 51), and is often used as the main correlate for protection against 
rotavirus disease. 
The development of homotypic or heterotypic immunity following natural rotavirus 
infection is also complex and incompletely understood.  It has been shown that after 
the first natural infection with rotavirus of a specific serotype, infants develop 
neutralising antibodies predominantly directed against that specific serotype 
(homotypic immunity).  Subsequent natural infections with rotavirus of even the same 
serotype seem to induce serotype cross-reactive response, i.e. heterotypic protection 
or protection against different serotypes (52).  Serotype-specific serum neutralising 
antibody responses have been used together with rotavirus-specific serum IgA as 
measures of “vaccine take” following administration of rotavirus vaccines.  
The immunity provided by natural rotavirus infections may explain why older children 
and adults are relatively protected against severe rotavirus disease compared with 
young infants or children.  It also forms the basis for immunisation with rotavirus 
vaccines.  In other words, a vaccine that mimics a mild asymptomatic rotavirus 
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1.5 Rotavirus Vaccines 
Immunisation with rotavirus vaccines is intended to mimic natural rotavirus infection 
by protecting against severe illness during subsequent natural rotavirus infections.  
Rotavirus vaccine development strategies have concentrated on the development of 
live-attenuated vaccines for administration by oral route.  Oral vaccines are more 
effective in producing secretory IgA antibodies that can operate at the luminal surface 
of the gut and intracellularly in infected luminal surface cells. Live attenuated vaccines 
replicate to produce immunity similar to that of a natural infection, with serum 
rotavirus-specific IgA and longstanding serum rotavirus-specific IgG production. 
RotaShield® was the first licensed rotavirus vaccine.  It was a simian-human 
reassortant, live-attenuated rotavirus vaccine containing a single human virus gene 
coding for VP7 and 10 genes of the simian virus.  It was licensed for universal use for 
infants aged 2-6 months in the United States in 1998.  However, it had to be 
withdrawn a year later when it was found to be associated with intussusception (3, 
53).  The risk for intussusception was greatest between 3 and 14 days after the first 
dose of RotaShield® (>20-fold increase), with a smaller 5-fold increase within 3-14 
days after the second dose (54).  Overall the estimated risk associated with the first 
dose of RotaShield® was approximately 1 case per 10,000 vaccine recipients (55).  
Baseline epidemiology and incidence of intussusception varies widely by region, the 
mean incidence is 74 per 100,000 among children aged <1 year (56). 
RotaTeq® (RV5, Merck, USA) is a pentavalent live-attenuated oral rotavirus vaccine 
developed from human and bovine parent rotavirus strains.  It carries G1, G2, G3, G4 
and P[8] human rotavirus surface proteins, the 5 most common circulating human 
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strains, each bound to a WC3 bovine strain.  It was licensed and recommended for 
universal use in the US in 2006.  It has a three dose schedule, with 2mls per dose. 
Rotarix® (RV1, GSK Biologicals, Belgium) is also a live-attenuated oral rotavirus 
vaccine.  It is a monovalent vaccine derived from a G1P[8] human rotavirus strain.  It 
has a two-dose schedule, given as 1ml per dose.  It was also licensed and 
recommended for use in US in 2006.  Rotarix® vaccine relies on the protection from 
rotavirus disease being heterotypic. 
For RotaTeq®, the manufacturer recommended the first dose to be administered 
between 6 and 12 weeks (up to 12 weeks 6 days), with subsequent doses given with 
an interval of at least 4 weeks, and all vaccine doses administered by 32 weeks and 6 
days.  For Rotarix®, the recommended schedule for first dose is between 6 weeks and 
14 weeks 6 days, and the second dose must be given by 24 weeks 6 days.  The age cut-
off were set by the manufacturers in order to avoid the age range at which idiopathic 
intussusception occurs (3).   
In 2014, India launched a monovalent rotavirus vaccine, Rotavac® (Bharat Biotech, 
India), which was developed in India following a multi-partner international 
collaboration.  Rotavac® (also known as 116E) contains a neonatal G9P[11] rotavirus 
strain.   It completed phase III efficacy and safety trial in India in 2013 (57), and was 
introduced into the India national immunisation programme in 2016.   This vaccine 
received pre-qualification from the WHO in January, 2018, which will enable its 
procurement for public health vaccination across the world (58). 
There are at least two other rotavirus vaccine candidates undergoing clinical trials.  
RV3-BB is a human neonatal strain (G3P[6]) isolated and developed in Australia and 
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had undergone Phase II trials in Indonesia and New Zealand.  BRV-TV is a tetravalent 
UK reassortant bovine vaccine containing a strain of bovine rotavirus and four human 
rotavirus G1-4 serotypes, being tested in developing countries. 
The United Nations’ Millennium Development Goal 4 (MDG4) called for a two-thirds 
reduction in mortality rate among children under 5 between 1990 and 2015.  
Diarrhoea is one of the main killers in children under five worldwide and one third of 
diarrhoeal deaths is attributable to rotavirus.  Prevention of this illness by vaccination 
especially in the poorest regions of sub-Saharan Africa and Southern Asia is therefore 
a simple intervention that can potentially have considerable impact on reducing global 
child mortality.  In 2009, RotaTeq® and Rotarix® were recommended by the WHO’s 
Strategic Advisory Group of Experts (SAGE) for inclusion in national immunisation 
programs in Africa and Asia (59).  In 2006, GAVI Alliance (formerly known as the Global 
Alliance for Vaccines and Immunisations) pledged funding to finance the purchase and 
introduction of rotavirus vaccines to the poorest countries (60).   
Table 1 Differences between rotavirus vaccines prequalified by WHO for global use as of June 
2018  
 RotaTeq® (RV5) Rotarix® (RV1) Rotavac® (116E) 
Composition/strains Pentavalent - 
contains G1, G2, 
G3, G4 P[8] human 
rotavirus proteins 











Dosing schedule 3 doses, 4 weeks 
apart 
2 doses 3 doses, 4 weeks 
apart 
Timing for first dose Between 6 weeks 
and 12 weeks 6 
days 
Between 6 weeks 
and 14 weeks 6 
days 
6 weeks - no 
documented upper 
limit age 




1.6 Rotavirus Vaccines – Efficacy and Effectiveness 
1.6.1 Vaccine Efficacy 
The pre-licensure safety and efficacy trials of both RotaTeq® and Rotarix® showed that 
both vaccines were highly efficacious, with RotaTeq® protection against severe 
rotavirus diarrhoea being 98% (61); and Rotarix® protection against severe diarrhoea 
being 85%, and 100% effective against the most severe cases (62).  These safety and 
efficacy trials involved over 60,000 participants each, which allowed a limited 
assessment of intussusception risk before licensure.  The protection conferred 
appeared to be against a broad range of circulating homotypic and heterotypic 
rotavirus strains during the trials (61, 62).  The clinical-efficacy substudy of RotaTeq® 
involved subjects from the United States and Finland (both countries of high income).  
Rotarix® trials were performed in 11 Latin American Countries (all middle income 
countries except Nicaragua which is a low income country) and to a very small extent 
Finland (a high income country).   
Other trials in high income countries also showed high vaccine efficacy:  Rotarix® 
efficacy against severe rotavirus gastroenteritis was 90.4% to 96.1% in European 
countries and high income Asian countries respectively (63, 64). 
However both RotaTeq® and Rotarix® vaccine efficacy have been shown to be 
significantly lower in clinical trials conducted in low income or developing countries 
when compared to developed countries.  Rotarix® efficacy was 49.4% in Malawi and 
76.9% in South Africa (39); RotaTeq® efficacy was 48.3% in Bangladesh and Vietnam, 
and 39.3% in sub-saharan Africa (65, 66), against severe rotavirus infections (Table 2). 
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Table 2 Efficacy of rotavirus vaccines determined in randomised, double-blind, placebo-
controlled clinical trials 
Vaccine Trial conducted in Efficacy of Full Course Vaccine Against 
Any Severity 
RVGE* 
Severe RVGE* All Cause 
Severe GE*  
RotaTeq® High income countries    
  USA, Finland (61) 74%~ 98%~ 58.9%# 
 Low income countries    
  Bangladesh, Vietnam (66) 42.5% 48.3% 27% 
  Ghana, Kenya, Mali (65) 30.5% 39.3% 10.6% 
Rotarix® High Income Countries    
  Singapore, Hong Kong and 
Taiwan (63) 
-- 96.1% 30.3% 
  Finland, Czech Republic, 
France, Germany, Italy, 
Spain (64) 
78.9% 90.4% 49.6% 
 Middle income countries    
  11 Latin American 
Countries + Finland (62) 
-- 85%^ 40% 
  South Africa (39) 64.2% 76.9% 44.1% 
 Low income countries    
  Malawi (39) 34.7% 49.4% 25.1% 
~ Against G1-G4 rotavirus gastroenteritis in the first full rotavirus season  
# Data from the main large scale study on efficacy after the first dose of vaccine at preventing hospitalization  
^ Against severe RVGE and RV associated hospitalization 




1.6.2 Vaccine Effectiveness and Public Health Impact 
As of December 2017, 86 countries worldwide have introduced rotavirus vaccines into 
their national immunisation programme, including 39 low–income, GAVI-eligible 
countries.  The use of rotavirus vaccines in public sectors is continuing to expand in 
GAVI-eligible countries.  In addition, rotavirus vaccines are also available in regional or 
pilot programmes in at least 7 other countries (67).    RotaTeq® and Rotarix® have also 
been licensed in over 100 countries and are available through the private market.   
Following introduction of rotavirus vaccines into the national immunisation 
programmes, population surveillance data from many countries had shown a marked 
reduction in rotavirus disease burden.   As shown in Table 3, where ecological study 
data are available, a decline in hospital admissions of 11-51% for all-cause acute 
gastroenteritis in children less than 5 years was seen in both high and low-middle 
income countries.  A more substantial decline, ranging from 50-84%, was seen in 
rotavirus hospitalisations in children less than 5 years old.  This reduction in rotavirus 
hospitalisations was sustained a few years after the initial introduction of national 
rotavirus immunisation (68). 
Several post-licensure studies of vaccine effectiveness against severe rotavirus disease 
using observational methods have shown findings consistent with clinical trial efficacy 
data for both vaccines.  There seems to be greater protection from rotavirus vaccines 
in high income countries (full course vaccine effectiveness ranged from 89.3-100% in 
Australia, USA and France)(69-72), than in middle or low income countries (full course 
vaccine effectiveness ranged from 40-76% in Brazil, El Salvador and Nicaragua)(73-76).   
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Despite the more modest vaccine effectiveness results in developing countries, a 
larger absolute number of severe cases of rotavirus have been prevented in these 
countries through rotavirus vaccination.  Particularly in Brazil and Mexico, introduction 
of rotavirus vaccination into the national immunisation programmes has seen a 
substantial decline in diarrhoeal deaths in children under 5 years of age.  In Brazil, a 
22% reduction in diarrhoea-related mortality was observed among children under 5 
years of age in 2007-2009 following introduction of rotavirus vaccine into their routine 
childhood immunisation programme in 2006 (77, 78).  Similarly, diarrhoea mortality 
declined by 46-50% among children under 5 years of age in Mexico in 2008-2011 (79, 
80).  A risk-benefit analysis estimated that a rotavirus vaccination programme would 
prevent over 600 rotavirus-associated deaths and about 1,500 hospitalisation in 
Mexican children by age 5, and over 600 rotavirus-related deaths and almost 70,000 
hospitalisations in Brazilian children under 5 (81). 
In addition to the above, introduction of national rotavirus vaccination has shown an 
additional benefit in many countries – indirect herd immunity effect.  In the first year 
after introduction of rotavirus vaccines into the national immunisation schedules, 
countries such as Australia, US and El Salvador observed a greater reduction in 
rotavirus gastroenteritis than expected for the vaccine coverage, and also a reduction 
in the rate of rotavirus gastroenteritis hospitalisation of up to 64% in the age group of 
children who were age-ineligible for rotavirus vaccination (69, 70, 82, 83).  This 
suggested that unvaccinated children were shielded from exposure to rotavirus by 
vaccinated children, thereby interrupting the transmission of the virus.  This herd 
effect became less prominent in the following year (70, 83). 
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Table 3 Effectiveness of Rotavirus Vaccine in Different Countries 
Country 
 
In <5 y.o. population, annual reduction of: Full Course Vaccine Effectiveness in 
Preventing RV Hospitalizations (Study type) Diarrhoea Mortality  Rotavirus Related Hospitalisations All-Cause Acute Gastroenteritis Hospitalisations 
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38% non-RVGE  
48%  in age <6  
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RV5 90% (cohort study) 
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29% reduction in medically 









In <5 y.o. population, annual reduction of: Full Course Vaccine Effectiveness in 
Preventing RV Hospitalizations (Study type) Diarrhoea Mortality  Rotavirus Related Hospitalisations All-Cause Acute Gastroenteritis Hospitalisations 
among children <2y.o. 














RV5 76% ≠ (case-control study) 










RV1 60% any dose 
 
¥ includes hospitalization or intravenous rehydration in ED ≠ includes ED visits and hospitalizations 
* inpatient and outpatient healthcare visits   ~during peak rotavirus season only  
RV5 = RotaTeq® RV1 = Rotarix®   RVGE = Rotavirus Gastroenteritis 
-- no data available
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1.7 Potential Factors Affecting Effectiveness of Oral Vaccines 
To date the exact mechanisms underlying the reduced effectiveness of oral rotavirus 
vaccines in resource-limited settings remain poorly understood but are likely to be 
multifactorial. As with oral rotavirus vaccines, other oral vaccines such as polio and 
cholera vaccines have also shown reduced effectiveness in resource-limited settings 
(95-97).  This suggests that there may be common mechanisms that limit immunity 
induced by oral vaccines in such environments.  These common mechanisms may also 
explain the lower rate of protection conferred by natural rotavirus infection in India 
compared with Brazil (38, 49).  Several hypotheses have been suggested to explain this 
gradient in vaccine efficacy between lower-income and more affluent countries.  
These hypotheses can largely be grouped into (1) factors that might impair the host 
immune response and (2) factors that might decrease the effective vaccine virus titre 
reaching the intestine.   
The factors that might impair the infant’s host response are: 
a) Micronutrient Deficiencies  
Certain micronutrients, such as zinc and vitamin A, have been shown to play 
essential roles in multiple aspects of the immune system, including the growth 
and function of T and B cells (98-101). Deficiency of these micronutrients is 
much more prevalent in developing countries (102, 103). Supplementation of 
vitamin A and zinc has been shown to reduce the incidence and severity of 
diarrhoea in children in developing countries (104, 105).  Impact of zinc and or 




b) Coinfection by Pathogenic Organisms  
The presence of other pathogens or disease state such as human 
immunodeficiency virus (HIV) infection, malaria, and other acute or chronic 
conditions of the host during vaccination is more common in infants in 
developing world.   It has been suggested that a high pathogen burden causing 
constant activation of inflammatory signalling may lead to hyporesponsiveness 
in induction of mucosal immunity (106), thus reduce the host’s immune 
response to the oral vaccine.   
c) Interfering Gut Flora  
The intestinal microbiota has been shown to play an essential role in 
promoting mucosal immune response, and may directly or indirectly affect 
vaccine efficacy.  Several observations have suggested that co-inhabiting 
bacterial and viruses could potentially decrease the immune response to live 
oral vaccine.  For example, infants who received a simultaneous dose of oral 
polio vaccine (OPV) with the first dose of a rotavirus vaccine have a lower 
response to the first dose of rotavirus vaccine (107, 108); concurrent acute 
diarrhoea affects the seroconversion rates to OPV (109); and, small bowel 
bacterial overgrowth has been shown to impair the immune response to live 
oral cholera vaccine (110).  As children in developing countries are more likely 
to have more enteric pathogens than those from developed countries, this 
may be a key factor in the lower immune response noted in resource-poor 
settings.   
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In addition, a recent case-control study of Ghanaian oral rotavirus vaccine 
responders and non-responders showed significant different faecal 
microbiome compositions between the two groups, and Ghanaian responders’ 
faecal microbiome compositions were more similar to Dutch infants’ 
(presumed responders) microbiome compositions.  This suggests that 
different intestinal microbiome may contribute to the priming of, or down-
regulation of the mucosal immune responses, and thus affect oral vaccine 
efficacy (111).   
d) Tropical Enteropathy 
Children in developing countries who are in continuous contact with a variety 
of enteric pathogens and with nutritional stresses are known to develop 
environmental enteropathy or tropical enteropathy (112).  This is manifested 
as abnormal intestinal mucosa with blunted epithelial villi in the small 
intestine, heightened inflammation, small bowel bacterial overgrowth, altered 
gut microbial composition and malabsorption of nutrients.  Environmental 
enteropathy disrupts gut integrity and function, though the degree to which it 
is linked to suboptimal oral vaccine efficacy is uncertain.  
The factors that might decrease the effective titre of the vaccine virus reaching the 
intestine are: 
a) Gastric Acid 
Rotavirus vaccine virus can be damaged by low pH in the stomach.  It is unclear 
whether there is a difference in levels of gastric acidity between infants in 
developing and developed countries, and whether such difference, if present 
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might influence vaccine take. Rotavirus vaccines are usually administered with 
a buffer solution to neutralise stomach acid.   
b) Maternal Antibodies Acquired Transplacentally or via Breast Milk - 




1.8 Maternal Antibodies 
The two mechanisms through which the mother’s immunity to rotavirus may inhibit 
her infant’s response to an oral rotavirus vaccine are either by the transfer of 
placental antibodies, or by the transfer of antibodies or specific components in 
breastmilk. 
1.8.1 Transplacental Transfer of Antibodies 
Women in developing countries have been shown to have a higher pre-existing level 
of serum IgG antibodies to rotavirus compared with those in developed countries 
(106, 113, 114). This is presumably from the greater burden of rotavirus disease in the 
community and thus more frequent maternal exposure to natural rotavirus infections.  
Titre of serum antibody is boosted during reinfection, symptomatic or asymptomatic 
(115).  IgA does not cross the placenta and therefore rotavirus-specific IgA is not 
present in cord serum (113).  However, it has been shown that there is a strong 
correlation between levels of rotavirus-specific IgG in maternal serum and levels 
transferred to infants in cord blood (113).  As a result, infants in developing countries 
acquire a higher level of transplacental anti-rotavirus IgG from their mothers.  It is 
unknown whether high titres of transplacental antibody in the infant can neutralise 
vaccine virus in the infant gut, and thereby inhibit a robust immune response to the 
vaccine, but it is certainly a postulated mechanism (116).   
1.8.2 Immune Component of Breast Milk 
Breast milk contains secretory IgA (sIgA), with the highest level shown to be present in 
the colostral phase (117) and then a decrease to transitional and mature milk. (117, 
118).   Rotavirus-specific IgA titre in breast milk has been shown to decrease by an 
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average of 4-fold over the 4-7 days between colostrum of days 1-3 postpartum and 
transitional milk of day 7-10 postpartum (113). 
Moon SS et al. (114) examined antibody profiles and neutralising activities against 3 
rotavirus vaccine strains (Rotarix®, RotaTeq® G1 strain, or 116E – a neonatal strain 
originally isolated in India) in breast milk specimens from lactating women in India, 
Vietnam, South Korea and the United States, who were breastfeeding their infants of 
4 to 29 weeks.  They found significantly higher IgA titres, and in vitro much higher 
neutralising activity against those rotavirus vaccine strains in breast milk from Indian 
mothers than that from American mothers.  The neutralising activity in one half of the 
milk specimens from Indian mothers could reduce the effective titre of Rotarix® (RV1) 
by approximately 2 logs, and RotaTeq® (RV5) G1 strain by approximately 1 log more 
than that of breast milk from American mothers.  Rotavirus-specific IgA and 
neutralising antibody titre in breast milk of South Korean and Vietnamese mothers fell 
in the intermediate range between that of Indian and American mothers.  This result 
suggested that high neutralising activity in breast milk could substantially reduce the 
effective titres of live oral rotavirus vaccines.  In other words, the presence of breast 
milk with high neutralising activity in the infants gut at the time of rotavirus 
immunisation, which may be seen in areas endemic of rotavirus disease such as in low 
income settings of India, can potentially lead to a significant reduction in the 
immunogenicity and efficacy of the vaccine.   
Siegrist (43) hypothesized that the influence of maternal antibodies on infant vaccine 
response was dependent on the relative ratio between the maternal antibody titres 
and the quatity of vaccine antigen present. Applying this to oral rotavirus vaccination, 
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when there are excess maternal antibodies to rotavirus such as in areas endemic for 
rotavirus disease, the effective vaccine titre may be reduced substantially enough by 
the presence of high neutralising activity in breast milk, rendering the vaccine viral 
load so low that its replication is further inhibited by the high level of maternal 
antibodies.  On the other hand when lower maternal antibody concentration is 
present, the vaccine viral titre is maintained above a certain threshold, and its 
replication less affected. 
Results from previous studies on the effect of breastfeeding on the response to oral 
rotavirus vaccines have been controversial and inconclusive.  A meta-analysis in 1990 
on rhesus rotavirus vaccine (RRV) reported reduced seroconversion rates among 
breast-fed babies (48% breastfed babies seroconverted compared with 70% bottle-fed 
babies) following a single dose of RRV (119).  Similarly, a recent European study 
demonstrated a small reduction in immunogenicity of Rotarix® in breastfed infants 
compared with exclusively formula fed infants but the vaccine efficacy was felt to be 
equally high between the two groups in the first rotavirus season, and only reduced 
slightly in the breast-fed group in the second season (120).  In contrast other studies 
examining Rotashield® and RotaTeq® have shown no differences in protection 
between breast and non-breastfed infants (121, 122).  Of note, in all except the study 
by Rennels et al. 1995 (121), the investigators only recorded whether or not an infant 




1.8.3 Non-Immune Component of Breast Milk  
Breast milk also contains nonspecific innate immune factors such as lactoferrin, 
lactadherin, mucin and butyrophilin.  These innate immune factors have previously 
been shown to inhibit rotavirus replication and infections in enterocyte-like cell-lines 
(123), and have also been reported to protect against symptomatic infection in infants 
(124, 125).  
Moon et al. (126) examined profiles of both rotavirus-specific IgA and nonantibody 
components in breast milk from mothers of developed (United States) and resource-
limited countries (India and South Africa) and investigated their possible associations 
with neutralising activity in breast milk.  Not only were levels of rotavirus-specific IgA 
and neutralising activity higher from Indian and South African breast milk, as seen in 
the initial study, there were also higher levels of lactoferrin and lactadherin in breast 
milk specimens from Indian and South African mothers than those form American 
mothers.  Levels of lactoferrin and IgA were independently positively associated with 
neutralising activity against rotavirus vaccine strains in Indian and South African 
specimens, but not in specimens the United States.  The inhibitory effect of lactoferrin 
appeared not only dose-dependent but also species-dependent.  Lactadherrin also 
exhibited some inhibitory activity to the rotavirus vaccine strains but to a lesser extent 
than lactoferrin. 
This in vitro observation suggests that the high levels of sIgA in breast milk and innate 
immune factors (such as that seen in some developing country settings) in the infant’s 
gut at the time of vaccination with live-attenuated oral rotavirus vaccines, could 
potentially result in substantial reduction in effective vaccine titres.  The impact or 
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inhibitory effect on vaccine performance can be either independent or synergistic 
between rotavirus-specific antibodies and non-antibody components of breast milk.    
1.8.4 Summary 
Even though there are a number of hypotheses to explain the heterogeneity in 
efficacy of the current rotavirus vaccines, definitive mechanistic studies are lacking.  
There are also conflicting results surrounding the role of maternally acquired 
antibodies. The exact mechanism affecting vaccine efficacy is likely to be 
multifactorial, involving complex interactions between maternal antibodies and infant 




1.9 Hypothesis and Aims of Study 
Hypothesis 
We hypothesize that rotavirus specific maternal antibodies, passively acquired via the 
placenta or through breast milk, may inhibit the infant’s immune response to live-
attenuated oral rotavirus vaccines in a dose-dependent manner. We hypothesize that 
the inhibition of infants’ immune response will be more pronounced when the first 
dose of vaccine is administered at birth than when it is administered at 8 weeks, given 
that the highest titre of maternal antibodies in breast milk (sIgA) is present in 
colostrum, and decreases in the transitional and mature milk (117, 118).  Similarly, 
transplacental IgG titre is highest at birth and start to decline in the first few weeks of 
life.   
Aims of Study 
The primary aim of this study is to determine the relationship between passively 
acquired rotavirus specific maternal antibodies via colostrum/breast milk at the time 
of first active dose of a rotavirus vaccine, and the infants’ level of IgA response after 
three doses of vaccine when received as a neonatal or an infant schedule, and after 
one dose in the neonatal schedule.    
This study also explore the effect of transplacental rotavirus specific maternal IgG and 
serum neutralising antibodies on infants’ level of IgA response, cumulative stool 
excretion of vaccine virus and cumulative vaccine take after three doses of vaccine 
when received as a neonatal or an infant schedule, and after one dose in the neonatal 
schedule.   
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This study also aims to describe the titres of rotavirus specific IgA in breast milk from 




2 Study Design 
2.1 Development of RV3-BB Rotavirus Vaccine 
RV3 is a human neonatal rotavirus strain (G3P[6]) identified in the stool of 
asymptomatic healthy full term infants in Melbourne obstetric hospital nurseries in 
the 1970s.  A prospective active surveillance study in a cohort of 44 RV3 infected 
neonates showed natural infection with RV3 in the neonatal period to be 100% 
protective against severe rotavirus disease and 65% protective against moderate 
disease throughout the first 3 years of life (48).  Protection against rotavirus disease 
appeared heterotypic, as neonates infected with RV3 had subsequent protection 
against other circulating strains in the community.  In addition, despite this strain 
being endemic in neonatal nurseries, it has never been detected in faeces from 
children admitted to hospital with severe gastroenteritis, and did not infect siblings of 
infants discharged home from the nurseries still excreting the virus.  RV3 was 
therefore considered an ideal neonatal vaccine candidate targeting disease prevention 
from birth or the newborn period. 
RV3 as a live attenuated oral vaccine was initially prepared as a low titre vaccine at 6.5 
x 105 fluorescent cell forming units (fcfu)/ml in the 1990s (the maximum titre available 
at the time).  This was tested in phase I and II clinical trials in Melbourne in the 1990s 
(127, 128).  Phase I trial of a single 1ml dose administered to 10 each of healthy young 
men, 3-4-year-old children and 3 month old infants showed RV3 vaccine to be safe 
and well tolerated (127).  Phase II trial (128) was conducted in 60 3-month old infants: 
20 received vaccine without soy formula as buffer, 20 received vaccine preceded by 
soy formula, and 20 received placebo preceded by soy formula.  Of vaccine recipients, 
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46% developed immune response of significance (sero-conversions and/or 
coproantibody immune response).  Post-trial surveillance showed vaccine recipients 
with an immune response were partially protected against rotavirus disease during 
the subsequent first rotavirus season (protective efficacy 54%).  Protection appeared 
to be heterotypic.  This “sub-optimal” immunogenicity and efficacy was felt to be 
related to the low dose of virus in the vaccine. 
Higher titre second generation RV3 vaccine (RV3-BB) was subsequently developed to 
an average of 8.3 x 106 FFU/ml in a WHO-approved Vero cell line.  It was tested in a 
Phase I trial at the Royal Children’s Hospital and Murdoch Childrens Research Institute 
(MCRI) in Melbourne between 2009 and 2011 (129).  60 participants: 20 adults aged 
18-50 years, 20 children aged 3-8 years and 20 infants aged 6-8 weeks were recruited 
(10 vaccine and 10 placebo per age cohort).  A single dose of RV3-BB was shown to be 
well tolerated in all participants.  In the infant cohort, vaccine take (defined as a 3-fold 
rise in serum anti-rotavirus IgA or serum neutralising antibody (SNA) from baseline at 
day 28 post dose, or evidence of RV3-BB viral replication in the faeces by RT-PCR 
analysis 3-6 days post post-vaccination) was demonstrated in 8/9 infants who received 
single dose RV3-BB.   
Due to the decision to include commercial rotavirus vaccines into the National 
Immunisation Programme in Australia in 2007, it has been necessary to conduct the 
Phase II trial of RV3-BB elsewhere.  Dunedin, New Zealand as a representative of a 
developed country setting was chosen to be the place to conduct the Phase IIa trial, 
whereas Phase IIb trial was conducted in Yogyakarta, Indonesia as a representative of 
a developing country setting.  
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Conduct of the Phase IIa trial of RV3-BB in Dunedin provided an opportunity to explore 
the effect of passively acquired rotavirus specific maternal antibodies (via placenta 
and/or breast milk) on the immune response to a rotavirus vaccine, in this case the 






2.2 Phase IIa RV3-BB Clinical Trial  
The Maternal Antibodies Study was conducted in parallel to the RV3-BB Phase IIa 
clinical trial (130).  A brief description of the conduct of theRV3-BB Phase IIa trial is 
therefore necessary as follows.  The Phase IIa RV3-BB trial was conducted at the 
Department of Women’s and Children’s Health, University of Otago and the Dunedin 
Hospital.  This was a prospective, double-blind, randomised, placebo-controlled trial to 
assess the safety, tolerability and immunogenicity of the RV3-BB vaccine following 3 
doses.  A neonatal dose was included for the first time.   
Vaccination from the newborn period is thought to have potential major advantages 
over the current licensed vaccine administration schedule, for which rotavirus 
vaccination does not commence until infants are 6 weeks of age.  Potential benefits of 
a neonatal dose include: targeting protection from rotavirus disease from birth 
especially in resource-poor settings with a high burden of rotavirus disease in early 
infancy; easier access to mother and baby before they leave a health care setting 
following delivery; and reducing the risk of intussusception by providing the first dose 
of vaccine at an age when intussusception is very rare. 
Potential (parents/guardians of) participants were sent written information 
antenatally between 28-32 weeks gestation, inviting them to participate in the clinical 
trial.  If they did not opt out at that time, they were contacted by phone and a home 
visit arranged for more detailed discussion of the trial.  If they were willing to 
participate in the trial, cord blood consent was signed either at this antenatal visit, or 
at a second antenatal visit prior to delivery.  This allowed collection of cord blood at 
delivery.  Following delivery, as soon as was practical within 5 days, if the 
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parents/guardians remained interested in participating in the trial, the participants 
were approached to confirm suitability and eligibility for the trial.  At that time written 
informed consents were signed, a physical examination carried out and randomisation 
process commenced. 
93 healthy newborn infants ≥ 36 weeks gestation age were recruited from birth, and 
randomised to 3 groups: 31 randomised to a ‘Neonatal Vaccine Schedule arm’, 31 to 
an ‘Infant Vaccine Schedule arm’ and 31 to ‘Placebo arm’.  Key exclusion criteria were: 
known or suspected disease of the immune system; receipt of blood products prior to 
study entry; prior receipt of a licensed rotavirus vaccine; known or suspected 
significant congenital malformation; genetic disorder or neurological disorder. 
Each participant received 4 oral doses of 1 ml each of Investigational Product (RV3-BB 
Rotavirus Vaccine (8.3 x 106 fcfu/ml) or placebo) according to the schedule shown in 
Table 3.  Participants in the ‘Neonatal Vaccine Schedule Arm’ received 3 doses of RV3-
BB Rotavirus Vaccine, with the first dose administered between days 0-5 of age.  
Participants in the ‘Infant Vaccine Schedule Arm’ received 3 doses of RV3-BB Rotavirus 
Vaccine, with the first dose administered at approximately 8 weeks of age.  The 
second, third and fourth doses of Investigational Product for each participant were 
preceded by a 2 ml dose of antacid solution (Mylanta Original®).  Investigational 
product doses were separated from routine NIP immunisations by at least 10 days.  
Feeding was withheld for 30 minutes before and 30 minutes after Investigational 
Product administration.  
Cord blood was taken for baseline serology.  Blood samples were taken approximately 
28 days after the first, third and fourth doses of Investigational Product for safety 
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assessments, and to assess immune response.  Stool samples were obtained daily on 
days 1-7 following each dose of Investigational Product to assess for RV3-BB virus 
excretion as an indication of vaccine replication and therefore vaccine 
take/immunogenicity (131).   















































# Placebo ˆ Placebo ˆ # Placebo ˆ # 
# = Blood test 
ˆ = Daily stool samples collection on days 1-7 after administration of the investigational product 




2.3 Maternal Antibodies Study 
The Maternal Antibodies Study was conducted in parallel to the RV3-BB Phase IIa 
clinical trial.  This was an exploratory study of association, to examine the impact of 
passively acquired rotavirus specific maternal antibodies (via placenta and breast milk) 
on infants’ immune response to an oral rotavirus vaccine, RV3-BB.   
2.3.1 Study Objectives 
Primary Objective: 
1. To examine the relationship between the level of IgA in colostrum or breast 
milk at the time of first active dose of RV3-BB rotavirus vaccine, and 1) IgA response 
and 2) cumulative stool excretion following 3 doses of RV3-BB rotavirus vaccine, when 
given as a) a neonatal and b) an infant schedule.  
Secondary Objectives: 
2. To examine the relationship between the level of IgA in colostrum and 1) IgA 
response and 2) cumulative stool excretion following 1 dose of RV3-BB rotavirus 
vaccine when given as a neonatal dose. 
3. To examine the relationship between the level of IgG in cord blood and 1) IgA 
response and 2) stool excretion following 3 doses of RV3-BB rotavirus vaccine when 
given as a) a neonatal and b) an infant schedule.  
4.  To examine the relationship between the level of IgG in cord blood and 1) IgA 
response and b) stool excretion following 1 dose of RV3-BB rotavirus vaccine when 
given as a neonatal dose. 
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5.  To examine the relationship between serotype-specific serum neutralizing 
antibody (SNA) in cord blood and 1) IgA response and 2) cumulative stool excretion to 
RV3-BB rotavirus vaccine when given as a) a neonatal and b) infant dose following 3 
doses of vaccine. 
6. To examine the relationship between serotype-specific SNA in colostrum or 
breast milk at the time of first active dose of RV3-BB rotavirus vaccine, and 1) IgA 
response or 2) cumulative stool PCR response to RV3-BB rotavirus vaccine when given 
as a) a neonatal and b) infant dose following 3 doses of vaccine. 
7.  To describe the level of rotavirus-specific IgA in breast milk over the first 28 
weeks of age. 
8.  To describe the level of serotype-specific SNA in breast milk over the first 28 
weeks of age. 
2.3.2 Ethics 
Ethics approval was obtained from the Lower South Regional Ethics Committee, New 
Zealand (LRS/12/01/004). 
2.3.3 Recruitment and Consent 
Mothers of all of the 93 participants from the Phase IIa Clinical Trial were invited to 
participate in this study, with written information provided at the same time as the 
antenatal visit for theRV3-BB Phase IIa Clinical Trial (here forth referred to as Phase IIa 
trial).  Recruitment and consent to participate in this study was obtained postnatally 
after the written informed consent was signed for the Phase IIa trial.  This consent also 
included consent for the results of stool, cord blood and blood, and data collected 
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from the Phase IIa trial to be used in this study.  Baseline characteristics including 
maternal parity, weight, height, ethnicity, chronic medical issues and smoking status 
were collected. 
2.3.4 Inclusion and Exclusion Criteria 
Inclusion Criteria 
Infants must fulfil all of the following conditions or characteristics in order to be 
considered for enrolment into the Phase IIa trial and therefore the Maternal 
Antibodies Study: 
1. Infant is 0-5 days of age at the time of randomisation.  
2.  Infant is in good health as determined by clinical judgement, including a 
medical history and physical examination which confirms the absence of a 
current or past significant disease state  
3.  The infant was born full term (≥36 completed weeks gestation), with a birth 
weight ≥2500 g 
4. Infant resides in the Otago region, with Dunedin hospital as their referral 
hospital, and was born at the hospital, en-route or at home. 
5.  Infant’s parent(s)/guardian(s) are expected to be available for the duration 
of the study, and agree to adhere to all protocol requirements;  
6.  Infant’s parent(s)/guardian(s) have provided written informed consent 




Additional inclusion criteria for the Maternal Antibodies Study  
1. Intention to breast-feed and  
2. Willingness to provide breast milk samples at each blood collection time 
point. 
Exclusion Criteria 
Infants with any of the following conditions or characteristics were excluded from 
enrolment into the Phase IIa Clinical Trial and therefore the Maternal Antibodies 
Study: 
1. Any medical, psychiatric, or social condition that in the opinion of the 
Principal Investigator would prevent the infant’s parent(s)/guardian(s) from 
giving proper informed consent or from complying with the study protocol;  
2.  Infants with any moderate or severe illness, and/or who have a fever 
(≥37.5˚C axillary/oral/tympanic or ≥38.0˚C rectal) within the 48 hours 
preceding randomisation; 
3. Infants with a previous history of intussusception or other significant 
gastrointestinal disease; 
4. Infants with previous laboratory confirmed disease caused by rotavirus; 
5. Infants with known or suspected major congenital malformations or 
genetically determined disease;  
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6.  Infants with a known or suspected disease of the immune system or those 
who have received immunosuppressive therapy, including systemic 
corticosteroids;  
7. Infants with a known or suspected bleeding diathesis, or any condition that 
maybe associated with a prolonged bleeding time;  
8.  Infants who have ever received any blood products, including 
immunoglobulin, or for whom receipt of any blood product during the 
course of the study is anticipated;  
9.  Infants in whom the following vaccines or vaccine components are 
contraindicated: diphtheria toxoid, tetanus toxoid, acellular pertussis, 
conjugate Hib, pneumococcal conjugate, polio, hepatitis B, BCG. 
10. Infants who have received, or for whom there is intent during the study 
period, to immunise with any investigational or licensed vaccines (including 
live attenuated, inactivated or subunit vaccines,) other than the scheduled 
NIS vaccines or birth dose Hep B and/or BCG where indicated. 
11. Participation (current or planned) in another investigational study, or have 
ever received any investigational agent;  
12. Infants who have a household member with severe immunosuppression 
considered by Investigator to place them at risk of contracting disease from 
live oral RV3-BB vaccine from the participant 




14. Infants with a significant evolving neurological disorder.  
15. Infants with a biological mother with a known or suspected HIV infection 
(as their baby’s HIV status will not be able to be determined in time to 
allow safe participation).  
16. Infants for whom their parent(s)/guardian(s) are MCRI, University of Otago 
or Dunedin Hospital employees with direct involvement with the study 
investigators, or with direct involvement in the study.  
17. Infants who have been exposed (though prenatal exposure and/or 
breastmilk) in the last 4 weeks to medicinal products administered to the 
mother, of the following: glucocorticosteroids, cytotoxic drugs, hepatotoxic 
agents or blood products. 
2.3.5 Collection of Specimens 
Cord Blood 
Cord blood (5 ml) was collected immediately following birth in accordance with to the 
study protocol for the Phase IIa trial.  The cord blood was centrifuged, frozen and 
stored at the local Southern Community Laboratory (SCL) at Dunedin Hospital and 
batched for transfer to Australia.   No extra cord blood was required for the Maternal 
Antibodies Study. 
Colostrum and Breast Milk 
Colostrum (2.0ml) was collected from each participant 0-5 days after delivery.  Further 
samples of breast milk (3.0ml) were obtained at each of the visits when blood was 
drawn from the babies for immunogenicity – approximately 28 days after the first, 
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third and fourth doses of investigational product (see Table 5).  If participants were 
unable to express the milk during the visits, they were asked to express at home 
within the cut-of time (prior to day 6 for colostrum and within the same day as the 
blood draw for breast milk) and to store the colostrum/breast milk in the fridge at 
home until collected by the study staff within 48 hours of expressing.  These were 
then picked up by the study staff and delivered to the laboratory in a cooler bag.  Once 
collected, each colostrum and breast milk sample were divided into 2 aliqouts (1.0ml 
each of colostrum and 1.5ml each of breast milk) and stored frozen in Cryogenic Vials 
at the local Southern Community Laboratory (SCL) at Dunedin Hospital, prior to being 
batched for transfer to Australia.  
Blood Samples 
Blood samples were taken approximately 28 days following administration of the first, 
third and fourth doses of Investigational Product for the Phase IIa Trial.  Serum 
samples were centrifuged, divided into 3 aliquots, frozen and stored at the local SCL at 
Dunedin Hospital for transfer to Australia.  No further blood samples were required 
for the Maternal Antibodies Study.   
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Stool samples were obtained daily (if available) on days 1-7 following each dose of 
Investigational Product (vaccine or placebo) for the Phase IIa trial.  Once obtained, 
they were kept in the freezer at individual participants home before being picked up 
and delivered to SCL at Dunedin Hospital by study staff in cooler bags.  Upon arrival at 
the SCL laboratory, each specimen was divided into 1-3 aliquots, frozen and stored at 
SCL until batched for transfer to Australia.  No further stool samples were required for 
Maternal Antibodies Study. 
2.3.6 Storage of Specimens 
All the breastmilk, blood and faeces were stored at -70° freezer at SCL Dunedin 
Hospital in different boxes (box 1 milk for 1st aliquot of colostrum or breast milk, box 2 
milk for 2nd aliquot of colostrum or breast milk, and so on where applicable) prior to 
being shipped to the Enteric Virus Laboratory at MCRI in Melbourne, Australia. 
2.3.7 Transport of Specimens 
Each aliquot of specimens were batched and shipped separately by courier to the 
MCRI Enteric Virus Laboratory.  There were 4 shipments made throughout the study 
period.  Samples were kept frozen at -70° during shipment using dry ice.  Australian 




3 Laboratory and Statistical Analyses 
3.1 Laboratory Analysis 
All specimens of cord blood, blood, colostrum, breast milk and faeces were analysed 
at the Enteric Virus Laboratory at MCRI in Melbourne, Australia. 
3.1.1 Serum Rotavirus Antibody Assays 
Serum and cord rotavirus-specific IgA and IgG antibodies were measured by enzyme 
linked immunosorbent assays (ELISA) as previously described (132), using rabbit anti-
RV3 polyclonal antisera as the coating antibody and RV3-BB virus antigen or Vero cell 
lysate as the capture antigen in 96-well Immuno II plates (Nagle Nunc, Rochester, NY).  
Sera were diluted, added to appropriate wells and incubated overnight at 4°C.  End-
point titration was used for rotavirus-specific IgA, starting at a dilution of 1:20.  For 
rotavirus-specific IgG, two dilutions of sera were used (1:50 and 1:100).   All plates 
were washed prior to addition of biotinylated anti-human IgA or IgG and strepavidin-
horseradish peroxidase conjugate, to detect rotavirus antigen-IgA specific antibody 
complexes or rotavirus antigen-IgG specific antibody complexes.   
The levels of serum and cord rotavirus specific IgA and IgG were determined using a 
standard curve generated from sera known to contain specific anti-rotavirus IgA or 
IgG.  The positive sera known to contain rotavirus IgA was arbitrarily assigned a titre of 
250,000 Units (U)/ml, and that containing rotavirus IgG was arbitrarily assigned a 
value of 250,000U/ml (115).  Doubling dilutions provided a standard curve to calculate 
rotavirus specific IgA and IgG concentration of test sera samples.  Optical density (OD) 
values from ELISA assay of sera were compared with values on the standard curve in 
46 
 
order to calculate units of anti-rotavirus IgA or IgG for all test specimens.  The lower 
detection limit of the assay was 20U/ml.  If rotavirus IgA or IgG was not detected in a 
sample, the concentration assigned corresponded to 50% of the lower limit of 
detection of the ELISA (i.e. 10U/ml).   
3.1.2 SNA Titres 
Serum and breast milk neutralising antibody (SNA) titres against RV3-BB were 
determined using fluorescent focus reduction neutralisation assay (115, 132).   
Standard dilution of rotavirus antigen was incubated with serial dilutions of serum or 
breast milk for 60 minutes (4 fold: 1:100-1:6,400), prior to absorption onto MA104 
cells and incubation at 37°C overnight.  The cells were then fixed with acetone and 
stained with rabbit rotavirus specific polyclonal antisera and antigen detected using 
Alexa flour 488 goat anti-rabbit FITC conjugate.  The number of fluorescing cells were 
counted for all wells, including virus-serum/breast milk and virus alone, using a BD 
Pathway 855 Bioimager.  The neutralising titre was determined as the reciprocal of the 
dilution where a 50% reduction in fluorescence was observed (133). 
3.1.3 Colostrum/Breast Milk Rotavirus Antibody Assay 
Rotavirus specific IgA in colostrum and breast milk were measured by end point ELISA. 
Briefly, colostrum and breast milk samples were prepared for ELISA by centrifugation 
(10,000 x g) at 4 °C, the lipid layer was removed remaining supernatant collected.  
Each 96 well immunoplate was coated with rabbit anti-SA11 rotavirus polyclonal 
antisera at 37 °C for 2 h. Following this, the immunoplate was blocked with 2% w/v 
BSA in PBS at 37 °C for 1 h. Subsequently, SA11 rotavirus and MA104 cell lysate was 
added to appropriate wells incubated at 37 °C for 2h. Prepared milk samples were 
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then serially diluted and allowed to incubate overnight at 4 °C. Peroxidase conjugated 
rabbit anti-human IgA (Dako) was added to the immunoplate and incubated at 37 °C 
for 1.5 h. The immunoplate was incubated with TMB substrate solution for 10 min and 
read at a wavelength of 450nm. Data was reported as the highest reciprocal titre with 
an OD two-fold higher than background. Colostrum and breast milk was positive for 
rotavirus specific IgA if the colostrum/breast milk IgA titre was >20.   
3.1.4 Stool Excretion of RV3-BB Rotavirus Vaccine 
RV3-BB virus excretion in the stool was measured by reverse transcription-polymerase 
chain reaction (RT-PCR) amplification of the Rotavirus VP6 gene, using gene specific 
primers: the Invitrogen One step RT-PCR kit and Rot3 and Rot5 oligonucleotide 
primers (134).  The VP6 RT-PCR products were purified using QlAquick gel extraction 
kit according to the manufacturer’s protocol (Qiagen, Germany).  The purified DNA 
together with specific oligonucleotide primers was sent to the Australian Genome 
Research Facility, Melbourne, for sequence analysis using an Applied Biosystems 
3730xl DNA Analyser (Applied Biosystems, Foster City, CA, USA).  The resulting 
sequence was analysed using the Sequencher® Software program version 4.1 (Gene 
Codes Corp Inc., An Arbor, MI, USA), and identity determined using the BLAST server 





3.2 Statistical Analysis 
Demographic characteristics of the participants were categorized and tabulated, and 
presented using mean and standard deviations (SD) for continuous variables, medians 
and interquartile ranges for non-normal data, and numbers and proportions for 
categorical variables.  Levels of IgA response were presented as mean and SD.  IgA 
response, stool excretion and cumulative vaccine take were presented with numbers 
and proportions, all of which were presented separately for the two vaccine schedules 
(neonatal and infant).   
The analysis of the relationship between maternal antibodies and all outcomes was 
based on participants in the two active vaccination arms (neonatal and infant), and 
included all eligible participants who received all 3 doses of RV3-BB vaccine according 
to the Phase IIa trial protocol (130) and had at least one of serum IgA or stool 
excretion data following at least one dose of vaccine, and a sample of colostrum or 
breast milk at the time of administration of the first dose of vaccine and/or cord blood 
for analysis of IgG or SNA.   
Vaccine Take was defined as serum immune response of anti-rotavirus IgA or serum 
neutralising antibody of at least a threefold increase from baseline to 28 days 
following dose administration and/or detectable RV3-BB excretion in stools any day 
from day 3 to day 7 following administration of any dose of vaccine.  IgA responders 
have at least a threefold increase from baseline in serum IgA in the 28 days following 
vaccine administration.  Stool responders have detectable RV3-BB excretion in stools 
any day from day 3 to day 7 following administration of any dose of vaccine. 
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Separate linear regression models were used to explore the relationship between the 
i) level of IgA in colostrum/breast milk at 4 weeks ii) Cord SNA and iii) Cord IgG, and 
the serum log-transformed IgA levels following 3 doses of vaccine, in each vaccine 
schedule. In the neonatal schedule only, linear regression was also used to explore the 
relationship between the level of IgA in colostrum and serum log-transformed IgA 
levels following the first dose of RV3-BB.  Logistic regression models were used to 
explore the relationship between the level of IgA in colostrum/breast milk at 4 weeks 
and cumulative stool excretion following 3 doses of vaccine (infant and neonatal 
schedule separately) and following 1 dose of RV3-BB vaccine (neonatal schedule). 
Medians and IQRs of IgA in colostrum and breast milk at time of first active vaccine 
dose for participants are also presented separately for those with and without serum 
IgA or stool excretion and vaccine take after 3 doses of RV3-BB, by vaccine schedule. 
Initially our primary objective was to examine the relationship between the level of 
IgA in colostrum/breastmilk and cumulative vaccine take following 3 doses of RV3-BB 
rotavirus vaccine, using both schedules (neonatal and infant).  However given the 
cumulative vaccine take was so high we focussed on the components of cumulative 
vaccine take – serum IgA response and stool excretion as continuous as well as 
dichotomous variables in a post hoc analysis.  Placebo participants were excluded 
from this analysis given the focus on the immune response to the vaccine.  
Placebo group was used as a negative control to indicate the rate of natural infection 
with rotavirus in this study population.  Participants in the placebo group were 
included in the analysis if they received all 4 doses of Investigational Product (IP) 
according to the Phase IIa trial protocol (130) and had at least one of IgA or stool 
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excretion data following at least one dose of IP, and a sample of colostrum or breast 
milk at the time of administration of the first dose of IP and/or cord blood for analysis 
for IgG or SNA.  Analysis was done after 3 and 4 IP doses to describe the immune 
response to natural rotavirus infection. 
Finally, the level of breastmilk anti-rotavirus IgA titres over time, up to 28 weeks after 
birth are displayed graphically as medians and IQR at each time point.  Median levels 
instead of mean levels were chosen as the data was highly skewed.  All the available 
colostrum and breast milk, irrespective of randomised group, were analysed to assess 
this trend and changes in titres of anti-rotavirus IgA over the first 28 weeks (MA Study 
duration) in this population.   






95 participants were recruited to the Phase IIa Clinical Trial.  Of these, eight were 
recruited prior to the commencement of the Maternal Antibodies (MA) Study (Phase 
IIa Clinical Trial commenced prior to ethical approval being granted for the MA Study).  
87 mother-infant pairs were approached for the MA Study, of which 79 consented to 
and were included in the MA Study (91% of participants approached and 83% of total 
participants recruited to Phase IIa Clinical Trial).  Of the other eight Phase IIa Clinical 
Trial participants who did not participate in the MA Study, three were not eligible as 
they were no breast feeding, four did not consent to the MA Study (one declined due 
to anticipated low milk supply following previous mastectomy, one due to a previous 
problem with breast feeding, two declined due to personal reasons) and; one 
withdrew from the Phase IIa Clinical Trial but prior to receiving the first IP dose (Figure 
3).    
Of the 79 mother-infant pairs included in the MA Study, 24 were randomised to the 
Neonatal Vaccine Group, 27 to the Infant Vaccine Group, and 28 to the Placebo Group.   
One participant from the Neonatal Vaccine Group missed the second dose of Vaccine 
and was lost to follow up.  Two other participants from this group were excluded from 
analysis due to trial eligibility violation.  In the Infant Vaccine Group, one participant 
withdrew from the trial following the first IP dose due to perceived adverse event of 
diarrhoea, one was excluded after the first IP dose due to administration of blood 
product for other health reasons, and one declined the last dose of IP but continued 
with all other aspects of the study until completion.  Two participants were excluded 
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from analysis due to dosing outside window, and three due to eligibility violation.  In 
the Placebo Group, one participant was lost to follow up after the second IP dose, four 
were dosed outside window and two violated study eligibility and were excluded from 
analysis.   
Sixty-one participants (neonatal group: n=21, infant group n=19 and placebo group: 
n=21) were included in the analysis.  The 21 participants in the placebo group were 





Figure 3  Flow diagram of participants in the Phase IIa Trial and the Maternal Antibodies Study 
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4.1 Participant Demographics 
Demographic characteristics of the study population are summarised in Table 6.   
Table 6 Summary of demographic data for Maternal Antibody Study participants included in 
the analysis 
 Neonatal Group 
N = 21 
Infant Group 
N = 19 
Placebo Group 
N = 21 
Infant Characteristics    








Sex (Male) – n (%) 15 (71%) 12 (63%) 6 (28%) 






















































   
















Presence of Chronic 








Pregnancy – n (%) 
0 0 2 (9.5%) 




4.2 Number of Specimens Collected 
4.2.1 Breast Milk  
50/79 (63%) participants provided full sets of breast milk (BM) specimens for analysis, 
which included colostrum and BM taken at 4 weeks (BM1), 20 weeks (BM2) and 28 
weeks (BM3).  There were 79/79 (100%) specimens of colostrum and 71/79 (90%) 
specimens of breast milk at 4 weeks available for analysis.   
In the analysis group, 21/21 (100%) from the neonatal group and 17/19 (89%) from 
the infant group had breast milk at time of first their active vaccine dose for analysis.  
21/21 (100%) from the placebo group provided colostrum and 19/21 (90%) had breast 
milk at 4 weeks for analysis. 
4.2.2 Serum 
In the neonatal analysis group, 17/21 (81%) participants provided full sets of serum 
(serum at 4, 20 and 28 weeks) for analysis.  One participant had missing serum at 4 
and 28 weeks, and one had missing serum at 20 weeks but provided serum at 28 
weeks for analysis. 
In the infant analysis group, 15/19 (79%) participants provided full sets of serum for 
analysis.  Two participants had missing serum at 28 weeks but provided serum at 20 
weeks for analysis. 
In the placebo analysis group, 14/21 (67%) participants provided full sets of serum for 
analysis.  One participant had missing serum at 20 weeks but provided serum at 28 




4.2.3 Cord Blood 
In the analysis group, three participants (14%) from the neonatal group, one (5%) from 
the infant group and five (24%) from the placebo group had cord blood for analysis. 
Table 7 Number of samples included in the analysis in each analysis group 
 Neonatal Schedule 
Group (n=21) 
Infant Schedule Group 
(n=19) 
Placebo Group(n=21) 
Birth - Cord blood 18 
- Colostrum 21 
 
- Cord blood 18 
- Colostrum 19 
 
- Cord blood 16 
- Colostrum 21 
 
4 weeks - breast milk 20 
- venous blood 20 
 
- breast milk 17 
- venous blood 18 
 
- breast milk 19 
- venous blood 17 
 
20 weeks - breast milk 16 
- venous blood 20 
- breast milk 16 
- venous blood 18 
 
- breast milk 19 
- venous blood 20 
 
28 weeks - breast milk 12 
- venous blood 18 
 
- breast milk 13 
- venous blood 17 
 
- breast milk 16 





4.3 Exclusive Breast-feeding 
Table 8 showed the number of participants in each analysis group who were 
exclusively breast-feeding at the different time points when colostrum/breast milk 
and bloods were collected.  19/21 (90%) infants in the neonatal group and 15/19 
(79%) infants in the infant group were exclusively breast fed at birth and 4 weeks 
respectively, at the time of their first active vaccine dose.  After 3 doses of vaccine, 
13/21 (62%) were exclusively breast fed in the neonatal group at 20 weeks, and 9/19 
(47%) were exclusively breast fed in the infant group at 28 weeks (these infants are 
also taking some solids). 
Table 8 Number of participants exclusively breast feeding at birth, 4 weeks, 20 weeks and 28 







Placebo Group  
N=21 
At Birth 19 (90%) 18 (95%) 19 (90%) 
At 4 weeks 17 (81%) 15 (79%) 19 (90%) 
At 20 weeks 13 (62%) 10 (53%) 13 (62%) 





4.4 IgA in Colostrum or Breast Milk and Serum IgA and Stool 
Excretion Following 3 doses of RV3-BB Vaccine 
4.4.1 Neonatal Group 
Twenty (95%) of 21 participants in the neonatal primary analysis group had a positive 
vaccine take following three doses of RV3-BB vaccine (Table 9).  Only one participant 
(5%) did not demonstrate vaccine take following 3 doses of RV3-BB vaccine.   
Table 9 Summary of IgA in colostrum or breast milk at time of first active vaccine dose for 
participants with and without serum IgA or stool excretion and vaccine take after 3 doses of 
RV3-BB 
 Neonatal Group Infant Group¥ 
N (%) 
(N=21) 
IgA in Colostrum 
N (%) 
(N=19) 








response after 3 
doses RV3-BB 
      
Serum IgA response 




No serum IgA 
response 
  5 (24) 640 160-1280 
  5# (26) 80 65-140 
Stool excretion after 
3 doses RV3-BB 
   
   
Stool excretion 15(71) 80 20-640 15 (79) 80 40-160 
No stool excretion 6(29) 120 50-160 4 (21) 40 30-100 
Vaccine take after 3 
doses RV3-BB 
   
   
Positive vaccine take 20(95) 80 20-640 17 (89) 80 40-160 




2 (10) 20 
No. too 
small 
¥two participants with missing breast milk at 4 weeks 
≠one participant with missing post dose 3 serum IgA level, serum IgA level post IP dose 4 was 
used for analysis 
#one participant with missing post dose 4 serum IgA level, serum IgA level post IP dose 3 was 
used for analysis 
&one participant with missing post dose 4 serum IgA level, serum IgA level post IP dose 3 was 




Cumulative Serum IgA Response 
A serum IgA response following 3 doses of RV3-BB vaccine was seen in 16 (76%) of 21 
participants.  The median IgA titre in colostrum was higher in serum IgA non-
responders than the responders (640 vs 80) but there was overlap in the IQRs of IgA 
titre in colostrum between the two groups (Table 8).  No association between IgA titre 
in colostrum and serum IgA response after 3 doses of RV3-BB was demonstrated from 
the linear regression model (regression coefficient = -0.004 (95% confidence interval 
[CI] -0.0011, 0.0002)) (Figures 3 and 4).   
There was one participant with high colostrum IgA level of 5120 who had a positive 
albeit low serum IgA response (47.62 units).  Of the five non-responders, there was 
significant variability in colostrum IgA level, two had very high colostrum IgA levels of 
2560 and 1280, the others had colostrum IgAs of 640, 160 and negative (20) (Figures 3 
and 4).   
 
Figure 4 Scatterplot of IgA in colostrum against cumulative serum IgA response after 3 doses 




Figure 5 Scatterplot of IgA in colostrum against cumulative serum IgA response after 3 doses 
of RV3-BB (log scale) in the neonatal schedule group.  Linear regression coefficient:         -0.004 
(95%CI -0.0011, 0.0002).  Note: one missing post dose 3 serum IgA level.  
Cumulative Stool Excretion 
Stool excretion of vaccine virus was identified in 15 (71%) of 21 participants following 
3 doses of RV3-BB vaccine (Table 9).  The median IgA level in colostrum was higher in 
participants who did not demonstrate stool vaccine virus shedding than those who 
had stool vaccine virus shedding (120 vs 80) but there was overlap in the IQRs of IgA 
level in colostrum between the two groups (Table 9).  There was no clear relationship 
between IgA level in colostrum and cumulative stool excretion of vaccine virus 
following 3 doses of RV3-BB rotavirus vaccine, when given as a neonatal schedule 







Figure 6 Scatterplot of IgA in colostrum against cumulative stool excretion after 3 doses RV3-
BB in the neonatal schedule group (N = 21). 
4.4.2 Infant Schedule 
Nineteen participants in the infant schedule group were included in the analysis, 17 
(89%) of whom demonstrated positive vaccine take following three doses of RV3-BB 
vaccine (Table 9).  Only two participants (10%) did not demonstrate vaccine take 
following 3 doses of RV3-BB vaccine. 
Cumulative Serum IgA Response 
There were 14 (74%) of 19 participants in this group with a positive serum IgA 
response following 3 doses of RV3-BB rotavirus vaccine.   The median IgA titres in 
breast milk at 4 weeks were the same in serum IgA responders and non-responders 
(both 80), with overlap in the IQRs of IgA titres in breast milk at 4 weeks between the 
two groups (Table 9).  An association between IgA in breast milk and IgA response 
following 3 doses of RV3-BB was not demonstrated by linear regression (regression 
coefficient= -0.0007 (95% CI -0.0106, 0.012)) (Figures 7 and 8). 
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Of the five non-IgA responders, one did not provide breast milk at 4 weeks for 
analysis.  The other four showed significant variability in breast milk IgA levels at 4 
weeks, one had high level of 320, two had moderate level of 80, one had negative titre 
(20) of breast milk IgA at 4 weeks.  Two participants with no detectable IgA titre in 
breast milk were IgA responders.  Of the two participants with the highest IgA in 
breast milk at 4 weeks, one demonstrated a serum IgA response whilst the other did 
not (Figures 7 and 8).   
 
Figure 7 Scatterplot of breast milk IgA at 4 weeks (at time of first active vaccine dose) against 
cumulative serum IgA response after 3 doses of RV3-BB in the infant schedule group.  Note: 2 





Figure 8 Scatter plot of breast milk IgA at 4 weeks (at time of first active vaccine dose) against 
cumulative IgA response after 3 doses of RV3-BB (log scale) in the infant schedule group.  
Linear regression coefficient: -0.0007 (95%CI -0.0106, 0.012).  Note: 2 missing post dose 4 
serum IgA levels and 2 missing breast milk at 4 weeks levels. 
Cumulative Stool Excretion 
Stool excretion of vaccine virus was identified in 15 (79%) of 19 participants following 
3 doses of RV3-BB vaccine (Table 8).  The median IgA level in BM at 4 weeks was 
marginally higher in participants who demonstrated stool vaccine virus shedding than 
those who did not demonstrate stool vaccine virus shedding (80 vs 40), but there was 
overlap in the IQRs of IgA titres in breast milk at 4 weeks between the two groups 
(Table 8).  Figure 9 showed that there was no clear relationship between IgA in breast 
milk at 4 weeks and cumulative stool excretion of vaccine virus following 3 doses of 




Figure 9 Scatterplot of breast milk IgA at 4 weeks against cumulative stool excretion after 3 





4.5 IgA in Colostrum and Serum IgA and Stool Excretion after 
One Neonatal Dose of RV3-BB Vaccine, Neonatal Schedule 
 
Following a single dose of RV3-BB vaccine given at birth, 5/21 (24%) participants in this 
group demonstrated a positive vaccine take (Table 10). 
Table 10 IgA in colostrum and serum IgA response or stool excretion and vaccine take after 
one neonatal dose of RV3-BB 
# Level of IgA in Colostrum equals to 640 
Serum IgA Response 
Twenty of 21 (95%) participants had both IgA colostrum and post-dose-1-serum-IgA 
for analysis.  Of these, 3 (15%) participants showed a positive serum IgA response.  
The median and IQR of IgA titre in colostrum was lower in the serum IgA responders 
(median 20; IQR 20-80) compared with the non-responders (median 160; IQR 20-640), 
but there was overlap in the IQRs between the two groups.  There was no evidence of 
an association between IgA in colostrum and serum IgA response following 1 dose of 
RV3-BB (regression coefficient= -0.0001 (95%CI -0.0003, 0.0001)).  Two of the serum 
 








Serum IgA response after 1 dose 
RV3-BB 
   
Serum IgA response 3(15) 20 20-80 
No serum IgA response 17(85) 160 20-640 
Missing serum IgA 1#   
Stool excretion after 1 dose RV3-BB    
Stool excretion 3(14) 1280 20-2560 
No stool excretion 18(86) 80 20-160 
Vaccine take after 1 dose RV3-BB  
   
Positive vaccine take 5(24) 80 20-1280 
No vaccine take 16(76) 120 20-280 
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IgA responders had no rotavirus-specific IgA in colostrum (20 units), one had low level 
of IgA in colostrum of 80 units (Figures 10 and 11).   
 
Figure 10 Scatterplot of IgA in colostrum against serum IgA response after birth dose of RV3-
BB.  Note: 1 missing serum IgA level.  Neonatal group – after 1 dose. 
 
Figure 11 Scatterplot of IgA in colostrum against serum IgA response after birth dose of RV3-
BB (log scale).  Linear regression coefficient: -0.0001 (95%CI -0.0003, 0.0001).  Note: 1 missing 



















































Three (14%) of 21 participants had a positive stool excretion of vaccine virus after 1 
neonatal dose of RV3-BB vaccine.  The median colostrum IgA of those who 
demonstrated stool vaccine virus shedding was 1280 (IQR 20-2560) compared to 
those who did not demonstrate stool vaccine virus shedding who had a median 
colostrum IgA of 80 (IQR 20-160).  
Two of the participants who demonstrated stool excretion of vaccine virus had high 
colostrum IgA levels (1280 and 2560 respectively).  These participants did not have 
corresponding serum IgA response.  The other participant who demonstrated positive 
stool vaccine virus shedding had no detectable colostrum IgA level (20 units) and also 
had a positive post-dose-1-serum IgA response (Figure 12).   
 
Figure 12 Scatterplot of IgA in colostrum against stool excretion after birth dose of RV3-BB.  (N 
= 21).  Neonatal group – after 1 dose. 
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4.6 IgG in Cord Blood and Serum IgA Response and Stool 
Excretion  
4.6.1 Neonatal Schedule Following 3 doses of RV3-BB Vaccine 
Cumulative Serum IgA Response 
There was no significant association between IgG in cord blood and cumulative serum 
IgA response following 3 doses of RV3-BB vaccine in the neonatal group (Figures 13 
and 14) by linear regression (regression coefficient= 0 (95%CI -0.0001, 0)).   The serum 
IgA responder had slightly lower median cord IgG levels compared with the non-
responders (18600 vs 28437) but there was overlap in the IQRs between the two 
groups (Table 11). 
Table 11 IgG in cord blood vs serum IgA response or stool excretion and vaccine take after 3 
doses of RV3-BB 
















response after 3 doses 
RV3-BB 
      
Serum IgA response 
16 (76)≠ 18599.56 
7168.67-
29223.02 
14 (74)& 15878.94 
8485.19-
29157.38 
No serum IgA response 
  5 (24) 28437.01 
26397.1-
34566.11 




response after 3 doses 
RV3-BB 
     
 
Stool excretion 15(71) 21538.8 
7089.38-
30111.95 
15 (79)~ 20851.32 
11689.67-
29157.38 
No stool excretion 6(29) 26230.98 
15832.12-
41391.84 
4 (21) 24606.8 
8565.83-
41745.99 
Vaccine take after 3 
doses RV3-BB 
     
 




17 (89) 17020.43 
9820.1-
26159.51 





45654.6 No. too 
small 
^neonatal group - missing 3 cord IgG data  
~infant group – missing 1 cord IgG data 
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≠one participant with missing post dose 3 serum IgA level, serum IgA level post IP dose 4 was 
used for analysis 
#one participant with missing post dose 4 serum IgA level, serum IgA level post IP dose 3 was 
used for analysis 
&one participant with missing post dose 4 serum IgA level, serum IgA level post IP dose 3 was 




Figure 13 Scatterplot of cord IgG level against serum IgA response after 3 doses of RV3-BB in 






Figure 14 Scatterplot of cord IgG level against serum IgA response after 3 doses of RV3-BB (log 
scale) in the neonatal schedule group.  Linear regression coefficient: 0 (95%CI -0.0001, 0).  
Note: 3 missing cord IgG levels, 1 missing post dose 3 serum IgA level. 
 
Cumulative Stool Excretion 
The cord IgG level was marginally lower in participants who demonstrated stool 
vaccine virus shedding than those who did not demonstrate stool vaccine virus 
shedding (21539 vs 26231), but there was overlap in the IQRs between the two groups 
(Table 11).  There was no clear relationship between cord IgG and cumulative stool 
excretion of vaccine virus following 3 doses of RV3-BB vaccine, when given as neonatal 




Figure 15 Scatterplot of cord IgG against cumulative stool excretion after 3 doses RV3-BB 
vaccine in the neonatal schedule group.  Note: 3 missing cord IgG levels. 
4.6.2 Infant Schedule Following 3 doses of RV3-BB Vaccine 
Cumulative Serum IgA Response 
There was little evidence of an association between cord IgG and cumulative serum 
IgA response following 3 doses of RV3-BB vaccine in the infant group (Figures 16 and 
17) (regression coefficient= -0.0001 (95%CI -0.0001, 0)).  The responders had lower 
cord IgG levels than the non-responders (15879 vs 31100), with overlap in IQRs 




Figure 16 Scatterplot of cord IgG level against serum IgA response after 3 doses of RV3-BB in 




Figure 17 Scatterplot of cord IgG level against serum IgA response after 3 doses of RV3-BB (log 
scale) in the infant schedule group.  Linear regression coefficient: -0.0001 (95%CI -0.0001, 0). 
Note: 1 missing cord IgG level, 2 missing post dose 4 serum IgA levels. 
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Cumulative Stool Excretion 
There was no association between cord IgG and cumulative stool vaccine virus 
excretion following 3 doses of RV3-BB vaccine given as infant vaccine schedule (Figure 
18).  Median cord IgG levels were lower in those who demonstrated stool shedding of 
vaccine virus compared with those who did not (20851 vs 24607) but there was 
overlap in the IQRs between the two groups (Table 10).  
 
Figure 18 Scatterplot of cord IgG against cumulative stool excretion after 3 doses of RV3-BB 
vaccine in the infant schedule group.  Note: 1 missing cord IgG level. 
4.6.3 Neonatal Schedule Following 1 Neonatal Dose RV3-BB 
Vaccine 
Serum IgA Response 
There was no evidence of an association between cord IgG and serum IgA response 
following 1 neonatal dose of RV3-BB vaccine (Figures 19 and 20) (regression 
coefficient= 0 (95%CI 0, 0)).  Median cord IgG levels are similar between the 
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responders and non-responders (22860 vs 24025), with overlap in the IQRs between 
the two groups (Table 12). 
Table 12 Cord IgG vs serum IgA response and vaccine take after 1 neonatal dose of RV3-BB 
#missing 1 serum IgA response data 
^missing 3 cord IgG data 
 
Figure 19 Scatterplot of cord IgG level against serum IgA response after birth dose of RV3-BB.  










Serum IgA response after 1 dose RV3-
BB vaccine*# 
   
Serum IgA response 3(14) 22860.06 11435.03-34285.09 
No serum IgA response 17(81) 24024.77 10134.96-28830.02 
Stool response after 1 dose RV3-BB 
vaccine 
   
Stool excretion 3(14) 34566.11 17288.06-42610.6 
No stool excretion 18(86) 24024.77 10134.96-28830.02 
Vaccine take after 1 dose RV3-BB 
vaccine 
   
Vaccine take 5(24) 40138.121 25927.08-46946.36 




Figure 20 Scatterplot of cord IgG level against serum IgA response post birth dose of RV3-BB 
(log scale).  Linear regression coefficient: 0 (95%CI 0, 0).  Note: 3 missing cord IgG levels, 1 
missing serum IgA level. 
 
Stool Excretion 
Median cord IgG level was higher in those who demonstrated stool shedding of 
vaccine virus than those who did not (34566 vs 24025), but there was overlap in the 
IQRs between the two groups (Table 12).  There was no evidence of an association 
between cord IgG and stool excretion of vaccine virus following 1 neonatal dose of 





Figure 21 Scatterplot of cord IgG against stool excretion after birth dose of RV3-BB.  Note: 3 





4.7 SNA in Cord blood and Serum IgA Response and Stool 
Excretion 
4.7.1 Neonatal Group Following 3 doses of RV3-BB Vaccine 
Cumulative Serum IgA Response 
There was no association between SNA titre in cord blood and cumulative serum IgA 
response following 3 doses of RV3-BB vaccine, using a neonatal schedule (Figures 22 
and 23) (regression coefficient= -0.0003 (95%CI -0.0011, 0.0006)).  The median cord 
SNA levels were similar between the responders and non-responders (474 vs 448) 
with overlap in the IQRs between the two groups (Table 13). 
Table 13 Cord SNA vs cumulative IgA or stool response and vaccine take after 3 doses RV3-BB 
















response after 3 doses 
RV3-BB 
      
Serum IgA response 16 (76)≠ 474 147-1331 14 (74)& 251 141-408 
No serum IgA response 5 (24) 448 263-1046 5 (26)~# 1281 847-1631 
Cumulative Stool 
response after 3 doses 
RV3-BB 
   
   
Stool excretion 15(71) 251.5 
174.75-
1117.25 
15 (79)~ 312 185-761 
No stool excretion 6(29) 797.5 
454.5-
1705.25 
4 (21) 406 267-765 
Vaccine take after 3 
doses RV3-BB 
   
   
Vaccine take 20(95) 474 184-1331 17 (89) 307 169-591 




2  (11) 
1401 No. too 
small 
^neonatal group - missing 3 cord SNA data 
~infant group – missing 1 cord SNA data 
≠one participant with missing post dose 3 serum IgA level, serum IgA level post IP dose 4 was 
used for analysis 
#one participant with missing post dose 4 serum IgA level, serum IgA level post IP dose 3 was 
used for analysis 
&one participant with missing post dose 4 serum IgA level, serum IgA level post IP dose 3 was 




Figure 22 Scatterplot of cord SNA titre against serum IgA response after 3 doses of RV3-BB in 
the neonatal schedule group.  Note: 3 missing cord SNA levels, 1 missing serum IgA level. 
 
 
Figure 23 Scatterplot of cord SNA titre against serum IgA response after 3 doses of RV3-BB (log 
scale) in the neonatal schedule group.  Linear regression coefficient: -.0003 (95%CI -0.0011, 
0.0006).  Note: 3 missing cord SNA levels, 1 missing serum IgA level. 
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Cumulative Stool Excretion 
There was no association between cord SNA and cumulative stool excretion of vaccine 
virus following 3 doses of RV3-BB vaccine, when given as neonatal schedule (Figure 
24).  The median cord SNA levels were lower in participants who demonstrated stool 
vaccine virus shedding than those who did not demonstrate stool vaccine virus 
shedding (252 vs 798) but there was significant overlap in the IQRs between the two 
groups (Table 12). 
 
Figure 24 Scatterplot of cord SNA against cumulative stool excretion after 3 doses of RV3-BB 
vaccine in the neonatal schedule group.  Note: 3 missing cord SNA levels. 
 
4.7.2 Infant Group Following 3 Doses of RV3-BB Vaccine 
Cumulative Serum IgA Response  
The median cord SNA level was lower in the serum IgA responders than in the non-
responders (251 vs 1281) though there was wide variability (range 141-408 units for 
responders and 847-1631 units for non-responders) but no overlap between the two 
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groups (Table 13).  However there were only 4 serum IgA non-responders in this group 
with cord blood sample for analysis.  There was therefore little evidence of an 
association between cord SNA and cumulative serum IgA response following 3 doses 
of RV3-BB vaccine (regression coefficient= -0.0018 (95%CI -0.0035, -0.0002) (Figures 
25 and 26).   
 
Figure 25 Scatterplot of cord SNA level against serum IgA response after 3 doses of RV3-BB in 





Figure 26 Scatterplot of cord SNA level against serum IgA response after 3 doses of RV3-BB 
(log scale) in the infant schedule group.  linear regression coefficient: -.0018 (95%CI -0.0035, -
0.0002).  Note: 1 missing cord SNA level, 2 missing serum IgA levels. 
 
 
Cumulative Stool Excretion 
There was no association between cord SNA and cumulative stool excretion of vaccine 
virus following 3 doses of RV3-BB vaccine, when given as infant schedule (Figure 27).  
The median cord SNA levels was lower in participants who demonstrated stool vaccine 
virus shedding than those who did not demonstrate stool vaccine virus shedding (312 




Figure 27 Scatterplot of cord SNA against cumulative stool excretion after 3 doses RV3-BB 
vaccine in the infant schedule group.  Note: 1 missing cord SNA level. 
 
4.7.3 Neonatal Schedule Following 1 Neonatal Dose RV3-BB 
Vaccine 
Serum IgA Response 
There was no association between cord SNA and serum IgA response following 1 
neonatal dose of RV3-BB vaccine (regression coefficient= 0 (95%CI -0.0003, 0.0003)) 
(Figures 28 and 29).  Median cord SNA level was higher in the responder compared to 
the non-responders (1000 vs 448) but there was overlap in the IQRs between the two 






Table 14 Cord SNA vs serum IgA response and vaccine take after 1 neonatal dose of RV3-BB 
^missing 1 serum IgA response data ~missing 3 cord SNA data 
*linear regression: 0 (95%CI -0.0003, 0.0003) 
 
Figure 28 Scatterplot of cord SNA level against serum IgA response post birth dose of RV3-BB.  











Serum IgA response after 1 dose RV3-
BB vaccine*^ 
   
Serum IgA response 3(14) 1000 550-1450 
No serum IgA response 17(81) 448 186.5-1226 
Stool response after 1 dose RV3-BB 
vaccine 
   
Stool excretion 3(14) 184 142-615 
No stool excretion 18(86) 474 214.5-1615.5 
Vaccine take after 1 dose RV3-BB 
vaccine 
   
Vaccine take 5(24) 615 163-1259.5 




Figure 29 Scatterplot of cord SNA level against serum IgA response post birth dose of RV3-BB 
(log scale).  Linear regression coefficient: 0 (95%CI -0.0003, 0.0003).  Note: 3 missing cord SNA 
levels, 1 missing serum IgA level. 
 
Stool Excretion  
Median cord SNA level was lower in those who demonstrated stool shedding of 
vaccine virus than those who did not (184 vs 474), but there was overlap in the IQRs 
between the two groups (Table 14).  There was no evidence of an association between 
cord SNA and stool excretion of vaccine virus following 1 neonatal dose of RV3-BB 




Figure 30 Scatterplot of cord SNA against stool excretion after birth dose of RV3-BB.  Note: 3 






4.8 SNA in Colostrum and Breast Milk at 4 Weeks and Serum IgA 
Response and Stool Excretion  
There was insufficient SNA data for colostrum or breast milk at 4 weeks for analysis. 
Only five of 21 infants in the neonatal group had colostrum SNA data, with colostrum 
SNA ranging from 100 (no detectable neutralising activity) to 334.  Of the available 
colostrum SNA data, two participants with the highest colostrum SNA had positive 
serum IgA response, one of whom also demonstrated stool vaccine virus shedding but 
not the other.  One participant with no detectable colostrum neutralising activity had 
a positive serum IgA response and stool vaccine virus shedding.  The other two 
participants who had no serum IgA response had detectable colostrum SNA in the 
100s, one of them had stool vaccine virus shedding but not the other.  
Only three of the 19 participants in the infant group had breast milk at 4 weeks SNA 
data.  None of them had detectable neutralising activity on breast milk at 4 weeks, 
one had positive serum IgA response, two had no serum IgA response, whilst all three 




4.9 Placebo Group 
The placebo group was used as negative control, to assess rate and immune response 
to natural rotavirus infection.  21 participants in the placebo group were included in 
the analysis.  Five of 21 (23.8%) participants in this group developed a positive serum 
anti-rotavirus IgA level following receipt of the placebo vaccination, of which one (5%) 
participant had positive serum IgA levels detected from 20 weeks of age (time of 
blood test after investigational product (IP) dose 3), and four (19%) from 28 weeks of 
age (time of blood test 4 weeks after IP dose 4).  The participant with a positive serum 
anti-rotavirus IgA level at 20 weeks had negative colostrum and BM1 IgA titres, and 
serum anti-rotavirus IgA rose further at 28 weeks.  The four participants with positive 
serum IgA levels at 28 weeks had colostrum IgA titres between 40 and 320 units, and 
IgA titres in breast milk at 4 weeks between 20 and 320 units.  Only one participant in 
this group has positive stool PCR for RV3-BB, seen at both 20 weeks and 28 weeks.  
This particular participant had IgA titres in colostrum and IgA in breast milk at 4 weeks 
of 40 and 20 respectively, and a positive serum anti-rotavirus IgA level at 28 weeks of 
66.4 units.  Most of the serum IgA achieved following natural rotavirus infection were 
relatively low, <100 units.  Only one participant had serum anti-rotavirus IgA >200 
units, and this participant had negative colostrum and BM1 IgA titres. 
Table 15 Seroconverters in the placebo group 










33 27403.31 320 160 22.01 34.06 0 0 
42  20 20 54.04 283.82 0 0 
52 99816.63 320 320 10 61.34 0 0 
56 24499.83 40 20 10 66.4 1 1 




4.10 Colostrum/Breast Milk IgA Titres over the Study Duration 
54/79 (68%) of the total colostrum samples were positive for rotavirus specific IgA, 
including 14/21 (67%) of the colostrum from the neonatal primary analysis group.  49 
of the 54 (91%) colostrum samples positive for rotavirus specific IgA had IgA level 
below 1000, and breast milk IgA stayed below 1000 over the first 28 weeks, except 
one infants who had IgA level in colostrum of 40 which rose to 5120 at 4 weeks and 20 
weeks before dropping to 640 at 28 weeks (Figure 31).  This mother had no history of 
gastroenteritis during the study period. 
There were 5 participants with colostrum IgA titre greater than 1000 (Figure 31).  
None of these women with colostrum IgA ≥1000 had documented gastroenteritis 
illness during their pregnancy.  Three participants had colostrum IgA of 1280 (Figure 
31), one halved and one quartered by 4 weeks, whereas one doubled to 2560 at 4 
weeks.  This latter mother had no documented gastroenteritis during the study period.  
One participant had colostrum IgA of 2560, which halved by 4 weeks (Figure 31).  This 
infant had stopped breast feeding by 20 weeks.  
 The highest IgA titre in colostrum in this study was 5120, seen in one participant.  At 4 
weeks, the breast milk IgA had fallen to a very low level and remained low thereafter.   
49/71 (69%) of available breast milk at 4 weeks samples were positive for rotavirus 
specific IgA, including 14/17 (82%) in the infant schedule group (two participants in 
this group did not provide breast milk samples at 4 weeks).  44 of the 49 (90%) breast 







Figure 31 Levels of breast milk IgA over the first 28 weeks postpartum in the MA study 
population.  Note: Time 1 = day 0-5 after birth; Time 2 = approx. 4 weeks after birth; 
Time 3 = approx. 20 weeks after birth; Time 4 = approx. 28 weeks after birth. 
 
Table 16 and Figure 32 showed median IgA titres in colostrum and breast milk over the 
first 28 week postpartum in all 3 cohorts of participants.  Median IgA titres were 
similar between colostrum and milk at 4 weeks (80), but IQR values were wider in 
colostrum (Figure 32).  Median IgA titres were the same between milk 2 (20 weeks) 
and 3 (28 weeks). 
Table 16 Median and IQR of IgA titre in colostrum and breast milk over the first 28 weeks 
postpartum in the MA study population 
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Figure 32 Mean and IQR IgA titre in colostrum and breast milk over the first 28 weeks 
postpartum, for all participants in the maternal antibody study irrespective of randomised 
group (N = 79).  Note: Colostrum (n = 79) was collected at birth; Milk 1 (n = 71) at 4 weeks; 







This study investigated the impact of breast milk and placentally derived rotavirus 
specific maternal antibodies on the infant’s immune response to an oral rotavirus 
vaccine, RV3-BB, administered using two different administration schedules – a 
neonatal and an infant schedule, in parallel to a rotavirus vaccine trial.   
5.1 IgA in colostrum or BM at 4 weeks and serum IgA and stool 
excretion following 3 doses of RV3-BB vaccine 
In this study, we did not demonstrate inhibition of serum IgA response or stool vaccine 
excretion following three doses of RV3-BB rotavirus vaccine by IgA in colostrum or 
breast milk, in either a neonatal schedule with the first dose of vaccine at age 0-5 days 
or an infant schedule with the first dose of vaccine at 8 weeks of age.  These findings 
are consistent with randomised trials from North India (135) and South Africa (136) 
which found that withholding breastfeeding for 30 minutes or one hour before and 
after RV1 vaccine administration had little significant effect on the rate of anti-
rotavirus IgA seroconversion (135, 136), or the geometric mean titres of serum anti-
rotavirus IgA   (136).  Interestingly, a recent Pakistan study showed that when 
compared with with-holding breast feeding for one hour, immediate breast feeding 
following vaccination of RV1 not only did not reduce seroconversion rate after two 
and three doses of RV1, but instead improved seroconversion rate following two 
doses of RV1 (137).  Although we did not aim to study the timing of breast feeding on 
vaccine take, infants in this study who were breast fed would most likely still have 
breast milk present in their stomach at the time of vaccination, despite a feeding 
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restriction time of 30 minutes pre and post-administration of the vaccine, as half 
gastric emptying time in infants is estimated to be 86 minutes (138). 
Breast milk contains both innate immune and antibody factors which have been 
shown to inhibit rotavirus replication in vitro (124, 139), and thus protect against 
rotavirus disease.  However, there is clearly a complex relationship between maternal 
antibody titres at the time of immunisation and viral load that affects the 
neutralisation of live viral vaccines.  Siegrist postulated that when there is an excess of 
maternal antibody, such as in rotavirus endemic settings and/or low viral load, there 
may be inhibition of viral replication and thus infant’s B and T cell responses (43).  
Conversely, it was also suggested that low titre maternal antibody in breast milk might 
both suppress and enhance B cell responses (44).  Other factors such as the rotavirus 
vaccine strain may also play a role, for example the RV3-BB vaccine is derived from a 
neonatal rotavirus strain which binds to specific receptors in the newborn gut and is 
integrin independent and, may inherently offer protection from maternal antibodies 
(140). 
In our study, only participants with an IgA titre in colostrum or breast milk of ≤160 at 
the time of the first active dose of vaccine achieved a serum IgA response of >200 
units.  It has been postulated that there may be a critical level of IgA antibody titre 
that could be associated with sustained protection after rotavirus vaccination.  A 
recent systematic review found that rotavirus vaccine efficacy during the first 2 years 
of life was lower among countries where the serum IgA geometric mean 
concentration or titer (GMC) was < 90 compared with countries with a GMC >90 (141).  
It could be that IgA in colostrum or breast milk reduces the duration of the serum 
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immune response despite evidence of an immediate post-immunisation response.  
This could potentially explain the differences in rotavirus vaccine efficacy between the 
developing and developed nations, as higher levels of antibodies in the ingested 
breast milk by infants in developing countries with endemic rotavirus infection may 
lower the IgA seroconversion post vaccination and therefore limit clinical protection.  
This needs to be explored in larger studies, preferably efficacy studies in a developing 
country setting where there would be more infants exposed to high colostral/breast 
milk IgA.  
Given that this study was conducted in parallel to the Phase IIa trial, breast milk was 
taken at 4 weeks which aligned with a study visit, and was used as an approximation 
of breast milk prior to the first vaccine dose in the infant arm given at 8 weeks.  As 
breast milk at 4 and 8 weeks is beyond the stage of transitional milk and is considered 
mature milk, minimal decline in rotavirus specific IgA level in breast milk was expected 
between 4 and 8 week.  If there was a slight decline in the IgA levels in breast milk 
from 4 to 8 weeks, it would have meant that should our hypothesis be true, the infant 
group should have higher vaccine take than the neonatal group, which was not the 
case.  A slight decline in IgA levels in breast milk from 4 to 8 weeks would not affect 
the comparison of responders and non-responders within the infant group, as both 
the responders and non-responders should have the same rate of decline in breast 
milk IgA levels.  The background rate of natural rotavirus infection in the first few 
months of life is low in this setting (<5% by 20 weeks as seen in the placebo group), 
therefore we would not expect there to be a rise in the IgA levels in breast milk from 4 
to 8 weeks.  
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5.2 IgG and SNA in cord blood and vaccine take 
A few recently published studies had attempted to assess the effect of transplacental 
antibodies on immune response to live oral rotavirus vaccine.  An inverse relationship 
has been reported between maternal serum anti-rotavirus IgG antibody and serum 
anti-rotavirus IgA level after two doses of RV1 (135).  Another study from India found 
that high titres of pre-existing rotavirus IgG, presumed to be a measure of 
transplacental IgG in the absence of elevated serum IgA titre, diminished the serum 
IgA immune response to the 116E rotavirus vaccine, but the inhibitory effect could be 
overcome in a dose-dependent manner (142).   
In contrast, in this study anti-rotavirus IgG and SNA in cord blood did not appear to 
affect serum IgA response RV3-BB or viral stool replication following one dose of RV3-
BB vaccine given in the neonatal period.  We also found no evidence for a dose-
dependent response as our data showed no relationship between level of 
transplacental anti-rotavirus IgA or SNA and vaccine take following three neonatal 
doses of RV3-BB vaccine.     
5.3 IgA in colostrum and serum IgA and stool excretion after 1 
neonatal dose of RV3-BB vaccine 
Following one single dose of RV3-BB given at birth, our results suggested no 
suppressive effect of IgA in colostrum on serum IgA response or stool vaccine virus 
shedding.  However only 24% of the participants demonstrated a positive vaccine take 
following a single neonatal dose of vaccine.  The small sample size in this study 
therefore made it hard to ascertain the true impact of colostrum IgA levels on the first 
dose of RV3-BB vaccine from this study.   
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A meta-analysis stated that immediate breast feeding impaired the immune response 
to a single dose of rhesus rotavirus vaccine (119).  However, subsequent doses of 
vaccine were shown to be associated with IgA sero-conversion (143).  It could be that 
the first dose of a rotavirus vaccine primes the immune system, with a serum IgA 
response only detected after three doses of vaccine.   
5.4 Rate of natural rotavirus infection 
Positive anti-rotavirus response in the placebo group reflects rate of natural rotavirus 
infection in this study population, which was 5% by 5 months (20 weeks) and 23.8% by 
7 months (28 weeks) of age.  Interestingly one participant was excreting RV3-BB 
rotavirus in the stool at both 20 and 28 weeks, which suggested presence of this strain 
in the community.    
Only 1 participant included in the analysis group (1/61, 1.6%) had a positive cord blood 
anti-rotavirus IgA level, which was just above detection limit.  This participant was 
from the neonatal group.  Excluding participants in the neonatal arm who received a 
birth dose of RV3-BB vaccine, none of the other study participants (in the infant and 
placebo arms) had positive serum anti-rotavirus IgA at 4 weeks, indicating that early 
neonatal natural rotavirus infection rate is minimal in this population  In contrast, 
background pre-vaccination (at 6 weeks) positive serum rotavirus IgA rate ranged 
from 9/353 (2.5%) in Pakistan (137) to 62/359 (17.2%) in India (142), though in the 
Indian study IgA level double the lowest detection limit was used as the cut off to 
indicate early neonatal rotavirus infection. 
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5.5 Cord blood and breast milk antibody levels 
There was a wide range of cord blood rotavirus IgG from the participants in this study.  
Over 98% (60/61) of our participants had detectable rotavirus IgG in the cord blood.  
Our cord rotavirus IgG level appeared higher than that reported in Indonesia (range 
372-28,000, median 2446, IQR 1276-5760) (113), but was comparable to the pre-
vaccination rotavirus IgG levels at 8 weeks of age reported in India (median 9140-
14962, range 894-85,360) (142).  Given that transplacental rotavirus IgG decreases 
over time, it can be assumed that cord rotavirus IgG level in India is higher than that 
seen in this setting.     
In the setting of this study as a representative of developed country, >91% of the 
colostrum had anti-rotavirus IgA titre of <1000 units, with a median IgA titre of 80 and 
IQR of 20-320.  As expected, this levels are much lower than that measured in a 
developing country setting such as Indonesia, where the median colostrum anti-
rotavirus titre was 640, with an IQR of 160-2560 (113).  The IgA titre in our breast milk 
at 4 weeks (mature milk) is more similar to that of US mothers and lower than that 
seen in Indian mothers (114).  Our milk also showed  a decreasing trend in IgA levels 
from colostrum to more mature milk, as has been seen before in a population of 
Indonesian women (113).  
5.6 Strengths and limitations 
This study provided a unique opportunity to describe breast milk and placentally 
derived maternal antibodies in parallel to a rotavirus vaccine trial.   The findings on the 
impact of maternally acquired antibodies on a dose of rotavirus vaccine given at birth 
are of particular interest as currently there is no other such available data.    
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A limitation to this study was the small sample size.  As the study was conducted in 
parallel to the Phase IIa Clinical Trial, participant number was predetermined.  This, 
coupled with high vaccine take found in participants in both groups (95% in the 
neonatal schedule group and 89% in the infant schedule group) limited our ability to 
identify an association between responders and non-responders.  Given this the 
findings from this study should be regarded as exploratory and hypothesis generating 
for future study.   
In addition the range of passively transmitted maternal anti-rotavirus antibodies levels 
was narrow, due to low rotavirus disease burden in this setting.  This also limits the 
ability to detect an association between maternal antibodies and immune response to 
the vaccine.  Repeating this study in a developing country setting will allow 
comparison with a much wider range of passively transmitted maternal antibody 





This study found no evidence that passively acquired colostrum and breast milk anti-
rotavirus IgA antibodies, and anti-rotavirus IgG and SNA in cord blood, were 
associated with a reduction in serum IgA response or stool vaccine virus excretion to 3 
doses of RV3-BB vaccine administered in a neonatal or infant schedule in New Zealand 
infants.  It also suggested no suppressive effect of anti-rotavirus IgA in colostrum on 
serum IgA response or stool vaccine virus shedding to a birth dose of RV3-BB.  The 
impact of maternal antibodies on the sub-optimal vaccine performance in regions with 
high rotavirus disease burden warrants further investigation.  Further studies involving 
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IMPACT OF ROTAVIRUS SPECIFIC MATERNAL ANTIBODIES ON IMMUNE 
RESPONSE TO RV3-BB ROTAVIRUS VACCINE (RV3-BB PHASE IIa 
MATERNAL ANTIBODIES SUBSTUDY) 
PARENT/GUARDIAN INFORMATION SHEET 
 
Thank you for taking time to read this information sheet.  Please inform us if you would like an 
interpreter to explain this information sheet to you. 
 
You and your child would have recently been invited to participate in a research project - The RV3-BB 
Rotavirus Vaccine Phase IIa Clinical Trial.  We would like to invite you to participate in this substudy of 
the above clinical trial.   
 
What is the substudy about? 
Current available rotavirus vaccine (RotaTeq® and Rotarix®) have shown reduced ability to protect 
against rotavirus in developing countries.  There is evidence that there are higher levels of maternal 
antibodies to rotavirus in developing countries compared with developed countries.  It is felt that these 
antibodies acquired via the placenta (cord blood) and breast milk (from breast feeding at the time of 
vaccination) may reduce vaccine response, and therefore reduce protection against rotavirus disease. 
 
What is the purpose of this substudy? 
Mothers’ antibodies can be transmitted passively to their babies via the placenta and also 
colostrums/breast milk. This substudy looks at the levels of mothers’ antibodies to rotavirus and how 
they may interact with the babies’ immune response to the rotavirus vaccine RV3-BB.  Does presence of 
maternal antibodies reduce the effectiveness of the vaccine, or does it have no effect?  
 
How many people will be involved in this substudy? 
Mother(s)/Guardian(s) of all the participants involved in the RV3-BB Rotavirus Vaccine Clinical Trial will 
be invited to participate in this substudy. 
 
What if I decline to participate in this substudy?  Will it affect my participation in the RV3-BB 
Rotavirus Vaccine Phase IIa Clinical Study? 
Participation in this substudy is entirely voluntary.  Even if you sign the consent form, you are free to 
withdraw from further participation at any time, without giving a reason. Declining to participate in this 
substudy will NOT affect your participation in the RV3-BB Rotavirus Vaccine Phase IIa Clinical Study.  
Participation in this substudy is not a pre-requisite for participating in the RV3-BB Rotavirus Vaccine 
Phase IIa Clinical Study. 
 
How long will I be in this study for? 
As with the RV3-BB Rotavirus Vaccine Phase IIa Clinical Trial, you will be in this substudy for 
approximately 6 months.   
 
 
What do I need to do to be in this substudy? 
We will ask your permission to use your baby’s blood results from the RV3-BB Rotavirus Vaccine Phase 
IIa Clinical Study for this study, so that we do not have to re-bleed your baby to test their immune 
response to the RV3-BB Rotavirus Vaccine.  However, we will need 2ml of colostrum (half a teaspoon) 
from you on day 3-5 after delivery, 3ml breast milk from you at each of the 3 visits when your baby has 
his/her blood taken for the RV3-BB Rotavirus Vaccine Clinical Trial.  These colostrums/breast milk 
samples will be spun down, frozen and stored at the Southern Community Laboratory before being 
transported to the Enteric Virus Laboratory in Melbourne for analysis. 
 
Your child would have been randomised into one of the 3 groups for the RV3-BB Rotavirus Vaccine 
Phase IIa Clinical Trial.  There will be no further randomisation for this substudy.   The following table 
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* = Blood test + breast milk collection 
 
How will colostrums/breast milk be collected? 
You will be asked to hand express your colostrum/breast milk.  This method will generally be adequate 
for collection of such small volume (2ml of colostrum/3ml of breast milk). 
 
What are the possible risks/side-effects/inconvenience to you or your child? 
The breast milk samples that we need are very small (half a teaspoon each time).  This is not harmful for 
you or your child and the small amount required by us should not interfere with breast feeding.   
 
What are the benefits for other people in the future? 
By studying these antibodies that babies get from their mothers through cord blood or breast milk, we 
can see what effect there is on the babies’ immune response to the rotavirus vaccine.   The result from 
this study may help us determine when the best time it is to give rotavirus vaccine for it to work most 
effectively.  We hope that this vaccine will be an effective and cheaper alternative rotavirus vaccine for 
children in New Zealand and in all countries around the world.  The vaccine will hopefully prevent 
hundreds of thousands of the deaths and hospitalizations caused by rotavirus every year. 
 
 
Please feel free to contact the researcher if you have any questions about this substudy: 
Dr. Mee-Yew Chen 
Contact telephone: 03-470 3881 
Department of Women’s and Children’s Health, 
University of Otago 









IMPACT OF ROTAVIRUS SPECIFIC MATERNAL ANTIBODIES ON IMMUNE 
RESPONSE TO RV3-BB ROTAVIRUS VACCINE (RV3-BB PHASE IIa 
MATERNAL ANTIBODIES SUBSTUDY): 
Ethics ref: LRS/12/01/004 
FULL CONSENT FORM  
English I wish to have an interpreter. Yes No 
Deaf I wish to have a NZ sign language interpreter Yes No 
Maori E hiahia ana ahau ki tetahi kaiwhakamaori/kaiwhaka pakeha 
korero. 
Ae Kao 
Cook Island Ka inangaro au I tetai tangata uri reo. Ae Kare 
Fijian Au gadreva me dua e vakadewa vosa vei au. Io Sega 
Niuean Fia manaka au ke fakaaoga e taha tagata fakahokohoko kupu. E Nakai 
Samoan Ou te mana’o ia I ai se fa’amatala upu. Ioe Leai 
Tokelaun Ko au e fofou ki he tino ke fakaliliu te gagana Peletania kin a 
gagana o na motu o te Pahefika. 
Ioe Leai 
Tongan Oku ou fiema’u ha fakatonulea. Io Ikai 
 
 I consent to the use of the cord blood, blood and stool analysis results of my child from 
RV3-BB Rotavirus Vaccine Clinical Trial (Ethics ref: LRS/11/07/026) for the purpose of this 
substudy (RV3-BB Rotavirus Phase IIa Maternal Antibody Substudy) 
 The reasons for the use of the result have been explained to me. 
  I consent to the collection of my colostrum and breast milk in this study 
 The reasons for the collection of my colostrum and breast milk have been explained to 
me. 
 
 I have had the chance to discuss the study and I am satisfied with the answers I have been 
given. 
 I understand that taking part in this study is voluntary (my choice) and I may withdraw 
from the study at any time, and this will in no way affect my health care. 
 I have had time to consider whether to take part in this study. 






□ I do □ I do not   consent to the storage of my colostrum and breast milk for use in 









 _______________                                     
Participant’s Name   Participant’s Signature   Date 
 
I have explained the project to the participant who has signed above, and believe that they 





 _______________                                     
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